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Small-Molecule Inhibitors Targeting Sterol 14α-
Demethylase (CYP51): Synthesis, Molecular Modelling and
Evaluation Against Candida albicans
Faizah A. Binjubair,[a] Josie E. Parker,[b] Andrew G. Warrilow,[b] Kalika Puri,[a] Peter J. Braidley,[a]
Esra Tatar,[a, c] Steven L. Kelly,[b] Diane E. Kelly,[b] and Claire Simons*[a]
Fungal infections are a global issue affecting over 150 million
people worldwide annually, with 750000 of these caused by
invasive Candida infections. Azole drugs are the frontline
treatment against fungal infections; however, resistance to
current azole antifungals in C. albicans poses a threat to public
health. Two series of novel azole derivatives, short and
extended derivatives, have been designed, synthesised and
investigated for CYP51 inhibitory activity, binding affinity and
minimum inhibitory concentration (MIC) against C. albicans
strains. The short derivatives were more potent against the C.
albicans strains (e.g., MIC 2-(4-chlorophenyl)-N-(2,4-dichloroben-
zyl)-3-(1H-imidazol-1-yl)propanamide (5f) <0.03 μg/mL, N-(4-
((4-chlorophenyl)sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-tria-
zol-1-yl)propanamide (12c), 1 μg/mL, fluconazole 0.125 μg/mL)
but both displayed comparable enzyme binding and inhibition
(5f Kd 62�17 nM, IC50 0.46 μM; 12c Kd 43�18 nM, IC50 0.33 μM,
fluconazole Kd 41�13 nM, IC50 0.31 μM, posaconazole Kd 43�
11 nM, IC50 0.2 μM). The short series had poor selectivity for
CaCYP51 over the human homologue, whereas the selectivity
of the extended series, for example, compound 12c, was higher
(21.5-fold) than posaconazole (4.7-fold) based on Kd values,
although posaconazole was more selective (615-fold) than 12c
(461-fold) based on IC50 values. Based on inhibitory activity and
selectivity profile, the extended series are the better of the two
series for further development.
Introduction
Fungal infections affect over 150 million people per annum,
750000 of which are invasive infections by Candida sp. The
incidence of life-threatening systemic infections caused by
Candida albicans, such as disseminated candidiasis and candi-
demia, has risen over the past several decades with mortality
rates between 46–75%.[1] An estimated 2 million people
annually contract oral candidiasis and a further 1.3 million
oesophageal candidiasis.[2] In addition, recurrent bouts of
vulvovaginal candidosis (thrush) affect at least 75 million
women annually,[3] thus indicating unmet need for better
treatments.
Fluconazole has become the first-line agent for treatment
and prophylaxis against invasive candidiasis with voriconazole
and itraconazole as alternative options (Figure 1).[4,5] The use of
posaconazole has been limited mainly for oropharyngeal or
oesophageal candidiasis and for prophylaxis in high-risk
patients owing to its erratic bioavailability and unpredictable
trough plasma concentration.[6] A new tetrazole-based drug
candidate VT-1161 (oteseconazole) has been described and
successfully completed Phase 2b clinical trials (Figure 1).[7,8]
Azole antifungals inhibit sterol 14α-demethylase (CYP51) result-
ing in depletion of ergosterol thereby affecting cell membrane
integrity. However, resistance to current azole antifungals in C.
albicans is becoming progressively more serious, posing a
threat to public health[9] and can be attributed to the
prophylactic use of azole drugs and prolonged treatment
regimens in the clinic.[10–12]
Azole resistance can arise through four main mechanisms.
The affinity for C. albicans CYP51 may be reduced through point
mutations leading to amino acid substitutions, the amount of
CYP51 present may be increased due to upregulation of the
gene and the efflux of azole from the cell may be increased due
to the overexpression of transporters. In addition, it is possible
for secondary mutations to occur which confer resistance such
as ERG3 null mutants that are resistant to azoles through a lack
of ERG3 activity leading to the production of 14-methyl
fecosterol when treated which is capable of supporting
membrane function, thus the fungistatic effect of the accumu-
lation of other 14-methylated sterols is circumvented.[13–16]
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Over 140 CaCYP51 mutations have been described with
single, double, triple and more recently quadruple mutations
identified from clinical isolates.[17,18] However, the majority occur
in drug-sensitive strains and are therefore unlikely to contribute
to azole resistance. CYP51 mutations associated with drug-
resistant strains primarily occur in the active site cavity (Y132H,
Y132F, K143R, G307S and S405F), those that interact with the
haem or are present in the Cys-pocket which may affect the
redox potential of the haem (K143R, G464S and R467K) and
residues located on the β5-hairpin (Y447H, G448E, G448V and
G450E) that may affect interaction with the electron partner
NADPH-cytochrome P450 reductase (CPR) potentially affecting
catalytic efficiency.[17–20]
The enzymatic properties of C. albicans CYP51
(CaCYP51)[18,21] and the first X-ray structures of this enzyme[22]
enable the computational study of CaCYP51 amino acid
substitutions and the inhibitory effect of new azole compounds,
whilst the X-ray structures of human CYP51[23] enable predic-
tions of compound specificity for the fungal CYP51 over the
human homologue to be made.
In this study N-benzyl-3-(1H-azol-1-yl/)-2-phenylpropana-
mides were used to explore binding and fit within CaCYP51 for
both short and extended derivatives (Figure 2) establishing
preliminary structure-activity relationships (SARs), exploring
additional binding interactions within the hydrophobic sub-
strate access channel of CaCYP51 and evaluating inhibitory
activity against CaCYP51 and MIC against C. albicans strains.
Results and Discussion
Chemistry
N-Benzyl-3-(1H-imidazol/triazol-1-yl)-2-phenylpropanamides (5)
were obtained by a three-step synthetic route commencing
with a trimethylborate (B(OMe)3) facilitated amidation
(Scheme 1). A range of coupling reagents were investigated for
the amidation step including carbonyldiimidazole, DCC, PyBOP,
TBTU and T3P however either yields were unsatisfactory or, in
the case of PyBOP, the product could not be isolated from the
phosphine oxide by-product.
The use of B(OCH2CF3)3 as the amidation reagent
[24] gave
very good yields; however, we opted to use the more readily
available and cheaper B(OMe)3 reagent which, when combined
with activated 4 Å molecular sieves to absorb the generated
water, gave satisfactory yields after solid-phase work-up
described by Sabatini et al.[25] (Table 1).
The hydroxy group of 3 was then converted to the mesylate
on reaction with methanesulfonyl chloride in the presence of
Et3N, which after purification by column chromatography gave
Figure 1. Chemical structures of azole antifungal agents.
Figure 2. N-Benzyl-3-(1H-azol-1-yl/)-2-phenylpropanamide skeletons used in
this study.
Table 1. Yields and melting points of amides (3) when using the B(OCH3)3
amidation method.
Cmpd R1 R2 Yield [%] Mp [°C]
3a H H 98 108–110
3b 4-F H 89 114–116
3c 4-Cl H 85 135–136
3d 4-Cl Cl 84 126–128
3e 2,4-diCl H 100 78–80
3f 2,4-diCl Cl 40 106–108
3g 4-CH3 H 100 96–98
3h 4-CF3 H 34 104–106
3 i 4-OCH3 H 98 126–128
3 j 3,4-diOCH3 H 83 116–118
3k NHBoc H 79 118–120
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the mesylate products (4) in yields ranging from 35–70%. The
mesylates (4) were then reacted with either the potassium salt
of imidazole or triazole or tetrazole (prepared in situ by treat-
ment of imidazole/triazole/tetrazole with potassium carbonate
in acetonitrile at 45 °C for 1 h) overnight at 70 °C. On reaction
with the imidazolate anion a mixture of two products was
generally obtained, the required imidazole (5) and the alkene
elimination product (6; Scheme 1).
Only the 4-chloro-mesylate product (4c) was reacted with
all three azole anions; in the case of imidazole and triazole only
the azole products (5c and 5k, respectively) were formed,
whereas on reaction with the tetrazole anion only the alkene
elimination product (6c) was formed, albeit in low yield
(Table 2).
Electron-withdrawing chloro substituents led to a prefer-
ence for the azole substitution product (e.g., 5c, 5d and 5e),
whereas the unsubstituted derivative or introduction of elec-
tron donating groups gave either exclusively or predominantly
the elimination alkene product (e.g., 6a, 6g, 6h and 6 i). The
ratio of substitution to elimination product may be rationalised
by the effects of these substituents on the acidity of the α-
proton, however this effect was not observed for the dimethoxy
substituted compound, with the imidazole product (5 j) pre-
dominating.
For the extended derivatives only the triazole derivatives
were prepared, as the triazole is the most commonly used azole
in antifungals and generally triazoles have greater CYP
selectivity than imidazoles owing to reduced basicity.[26] The
Boc protected triazole derivative 5 l was prepared in order to
then react, after Boc deprotection, with arylsulfonyl chlorides to
extend the compounds to explore additional binding inter-
actions/fit within the CYP51 active site.
The Boc protected triazole derivative 5 l was successfully
deprotected with trifluoroacetic acid in CH2Cl2 to give the
triflate amine salt 7 in 82% yield. Attempts to react the amine 7
with the arylsulfonyl chlorides (8, R=F or R=Cl), using either
excess Et3N in CH2Cl2 or pyridine as base and solvent, were
unsuccessful.
Therefore the aryl sulfonyl extension was introduced at an
earlier stage with the (4-(arylsulfonamido)phenyl)methanami-
nium 2,2,2-trifluoroacetate derivatives (9) prepared as previ-
ously described[27] and coupled with tropic acid (1). For these
extended compounds low yields were obtained when using B
(OMe)3 as the coupling reagent, however DCC/HOBt provided
acceptable yields (67–87%; Scheme 2). The resulting N-(4-
(arylsulfonamido)benzyl)-3-hydroxy-2-phenylpropanamides (10)
were then mesylated (11) and converted to the triazole
derivatives (12) as previously described. Reaction with the
triazolate anion resulted in a mixture of two products, the
required triazole (12) and the alkene elimination product (13;
Scheme 2), which was the major product for all derivatives.
Scheme 1. i) B(OCH3)3, CPME, 4 Å molecular sieves, 100 °C, o/n; ii) MsCl, Et3N, CH2Cl2, o/n; iii) a) K2CO3, imidazole/triazole/tetrazole, CH3CN, 45 °C, 1 h; b) 4, 70 °C,
1–24 h; iv) 5 l, TFA, CH2Cl2.
Table 2. The percentage of azole (5) and alkene (6) product and the ratio
obtained.
Cmpd R1 R2 Azole
[%]
Cmpd Alkene
[%]
Ratio 5/
6
Imidazole (X=Y=CH)
5a H H – 6a 62 0 :1
5b 4-F H 34 6b 39 1 :1.15
5c 4-Cl H 56 6c – 1:0
5d 4-Cl 4-
Cl
50[a] 6d 22 2.3 : 1
5e 2,4-diCl H 74 6e 11 6.7 : 1
5f 2,4-diCl 4-
Cl
41 6 f 37 1:0.9
5g 4-CH3 H 5 6g 59 1 :11.5
5h 4-CF3 H 4 6h 59 1 :16
5 i 4-OCH3 H 27 6 i 50 1 :1.84
5 j 3,4-di-
OCH3
H 51 6 j 23 2.2 : 1
Triazole (X=N, Y=CH)
5k 4-Cl H 77 6c – 1:0
5 l NHBoc H 84 6k 9 9.3 : 1
Tetrazole (X=Y=N)
5m 4-Cl H – 6c 23 0 :1
[a] The compound was then recrystallised from CH3CN to give 0.108 g,
26%.
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Antifungal susceptibility testing
The susceptibilities of the SC5314 and CA14C. albicans (azole
sensitive) strains to all novel azole derivatives (5, 7 and 12) were
determined (Table 3) using the standardized CLSI M27-S4 broth
dilution method.[28]
With the exception of the dimethoxy derivative (5 j), all the
short derivatives displayed antifungal activity against both C.
albicans wild-type strains SC5314 and CA14. However the chloro
derivatives were the most effective with 5d (R1=4-Cl, R2=Cl)
comparable with the standard fluconazole (MIC 0.125 μg/mL
against both strains) and 5f (R1=2,4-diCl, R2=Cl) more effective
than fluconazole with MIC<0.03 μg/mL against both strains.
The introduction of a chloro group at R2 was clearly beneficial
(5c vs 5d and 5e vs 5f) as was the presence of two chloro
substituents at R1 (5c vs 5e and 5d vs 5f). Generally, the more
lipophilic (clogP) the short derivative (5) the better the MIC
observed (Table 3). The MIC obtained was comparable whether
the azole group was an imidazole (5c) or a triazole ring (5k).
The free amine (7) was ineffective against both C. albicans
strains (MIC>16 μg/mL), while for the extended derivatives (12)
a trend was observed between MIC and clogP with the more
lipophilic derivatives more effective at inhibiting fungal growth,
for example: 12c, R1=4-Cl, clogP 3.46, MIC 1 μg/mL compared
with 12a, R1=H, clogP 2.9, MIC 4 μg/mL (Table 3).
Inhibition of CaCYP51 (IC50 determination)
CYP51 reconstitution assays containing 1 μM CaCYP51 were
performed as previously described.[30] For CaCYP51, the concen-
trations of fluconazole and novel compounds (5, 7 and 12)
were varied from 0 to 10 μM. Exemplar IC50 profiles for
fluconazole, 5d, 5f and 12c are shown in Figure 3. For a very
tight binding inhibitor of CaCYP51 an IC50 value equal to half
the enzyme concentration would be expected (~0.5 μM). In the
short series 5 the chloro derivatives 5d (R1=4-Cl, R2=Cl) and
5f (R1=2,4-diCl, R2=Cl) showed optimal inhibitory activity with
IC50 0.39 and 0.46 μM respectively compared with fluconazole
IC50 0.31 μM (Table 4). In addition, the 4-methoxy derivative (5 i),
showed promising inhibitory activity with IC50 of 0.91 μM. The
free amine (7) showed weaker inhibitory activity (IC50 1.96 μM).
The extended derivatives (12) all showed very good inhibitory
activity against CaCYP51 (IC50 0.20–0.79 μM), with the halide
derivatives 12b (R1=4-F, IC50 0.20 μM) and 12c (R1=4-Cl, IC50
0.33 μM) having similar activity to fluconazole (Table 4).
Previously IC50 values of 0.38 to 0.6, 0.2, 0.39 and 0.2 μM
were obtained for fluconazole, voriconazole, itraconazole and
Scheme 2. i) DCC, HOBt, EtOAc, 0 °C 30 min then RT o/n; ii) MsCl, Et3N, CH2Cl2, o/n; iii) a) K2CO3, triazole, CH3CN, 45 °C, 1 h; b) 11, 70 °C, 1–24 h.
Table 3. MIC values for compounds against C. albicans SC5314 and CA14
at 48 hours.
Cmpd MIC [μg/mL] (μM) clogP[a]
R1 R2 X SC5314 CA14
5b 4-F H CH 8 (24.7) 4 (12.4) 3.14
5c 4-Cl H CH 8 (23.5) 4 (11.8) 3.54
5d 4-Cl Cl CH 0.125 (0.33) 0.125 (0.33) 4.1
5e 2,4-diCl H CH 1 (2.67) 1 (2.67) 4.1
5f 2,4-diCl Cl CH <0.03 (<0.07) <0.03 (<0.07) 4.66
5g 4-CH3 H CH 8 (25.1) 8 (25.1) 3.47
5h 4-CF3 H CH 4 (10.7) 4 (10.7) 3.91
5 i 4-OCH3 H CH 8 (23.9) 8 (23.9) 2.86
5 j 3,4-diOCH3 H CH >16 (>43.8) >16 (>43.8) 2.73
5k 4-Cl H N 8 (23.5) 8 (23.5) 3.05
7 – – – >16 (>36.8) >16 (>36.8) 1.69
12a H – – 4 (8.67) 4 (8.67) 2.9
12b 4-F – – 4 (8.34) 2 (4.17) 3.06
12c 4-Cl – – 1 (2.02) 1 (2.02) 3.46
12d 4-OCH3 – – 8 (16.3) 4 (8.14) 2.77
Fluc 0.125 (0.41) 0.125 (0.41) 0.86
[a] clogP was determined using Crippen’s fragmentation.[29]
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posaconazole, respectively, using 1 μM CaCYP51 in CYP51
reconstitution assays.[18,21] Compounds 5d and 5f both had MIC
values comparable with or lower than fluconazole against
azole-susceptible C. albicans strains and low IC50 values
comparable with fluconazole (Table 4) against recombinant
CaCYP51 indicating both compounds are good biochemical
candidates for further study as antifungal agents. Compound
12c, whilst having a low IC50 value towards CaCYP51, had a MIC
value that was eight times higher than that of fluconazole,
suggesting a bioavailability problem within the C. albicans cells.
CYP51 reconstitution assays were also performed using
0.25 μM Δ60HsCYP51 in the presence of varying concentrations
of compounds 5d, 5f, 12c, fluconazole, voriconazole and
posaconazole and the inhibition profiles obtained are shown in
Figure 3 and Figure S4 in the Supporting Information. The
selectivity for CaCYP51 over the human homologue was
relatively poor for compounds 5d and 5f with an only
approximately eightfold difference in IC50 values (Table 5),
exhibiting a similar selectivity as ketoconazole.[21] This could
limit the use of these two compounds as antifungal drugs. In
contrast compound 12c exhibited high selectivity at 461-fold
(Table 5), which is similar to that observed with voriconazole
(390-fold) and better than the previously observed 175-fold
selectivity of itraconazole,[21] thus suggesting this compound
could be useful as an antifungal drug if uptake and bioavail-
ability could be improved in C. albicans by further refinement of
the chemical structure. However, compound 12c was less
selective than posaconazole (615-fold) and well behind the best
compound fluconazole, which exhibited over 4000-fold selectiv-
ity for CaCYP51 over the human homologue based on apparent
IC50 values. By comparison the tetrazole VT-1161 did not inhibit
Δ60HsCYP51 activity at concentrations up to 50 μM and
selectivity in excess of 2000-fold was predicted.[31]
CaCYP51 ligand binding affinity
The absolute spectra of the purified CaCYP51 and Δ60HsCYP51
(c S1A) were typical for cytochromes P450 isolated primarily in
the low spin state. Dithionite reduced carbon monoxide differ-
ence spectra (Figure S1B) produced the characteristic red-shift
of the Soret peak to ~450 nm[32] indicating the proteins were
isolated in their native state and confirmed by the CYP51
reconstitution assays used to determine azole IC50 values.
Figure 3. CYP51 azole inhibition profiles. Inhibition profiles for 5d (*), 5f (*),
12c (*) and fluconazole (*) were determined in CYP51 reconstitution assays
containing 1 μM CaCYP51 or 0.25 μM Δ60HsCYP51 with lanosterol as
substrate. IC50 determinations were performed in duplicate with mean values
shown along with standard deviations. Relative velocities of 1.00 correspond
to an actual velocity of 0.911�0.141 min  1 for CaCYP51 and
8.16�2.84 min  1 for Δ60HsCYP51.
Table 4. Binding affinity (Kd) and IC50 values for compounds against
CaCYP51.
Cmpd CaCYP51 Kd
R1 R2 X IC50 [μM]
a [nM]
5b 4-F H CH 1.41 87�27
5c 4-Cl H CH 1.01 60�4
5d 4-Cl Cl CH 0.39 17�5
5e 2,4-diCl H CH 0.99 83�26
5f 2,4-diCl Cl CH 0.46 62�17
5g 4-CH3 H CH 2.45 144�47
5h 4-CF3 H CH 2.21 85�19
5 i 4-OCH3 H CH 0.91 55�10
5 j 3,4-diOCH3 H CH 6.15 –
5k 4-Cl H N 4.32 167�17
7 – – – 1.96 –
12a H – – 0.54 115�16
12b 4-F – – 0.20 55�27
12c 4-Cl – – 0.33 43�18
12d 4-OCH3 – – 0.79 110�22
Fluc 0.31 41�13
[a] Curve-fitted IC50 values (vi= zo+ {vo/1+ ([I]/IC50)
n Mean Kd values of three
replicates are shown along with associated standard deviations.
Table 5. Selectivity of compounds for CaCYP51 (Ca) over Δ60HsCYP51 (Hs) based on Kd and IC50.
Cmpd Kd [nM] Selectivity IC50 [μM] Selectivity
Ca Hs Hs/Ca (fold) Ca Hs Hs/Ca (fold)
5d 17�5 45�13 2.6 0.39 3.37 8.6
5f 62�17 74�13 1.2 0.46 3.73 8.1
12c 43�18 923�509 21.5 0.33 152 461
fluconazole 41�13 38460�4840 938 0.31 ~1327 4281
posaconazole 43�11 204�63 4.7 0.2[18] 123[a] 615
voriconazole 10�2[21] 2290�120[21] 229 0.2[18] 78[a] 390
itraconazole 19�5[21] 92�7[21] 4.8 0.4[21] 70[21] 175
ketoconazole 12�3[21] 42�16[21] 3.5 0.5[21] 4.5[21] 9
Mean Kd values of three replicates are shown along with associated standard deviations. For IC50 determinations CYP51 assays contained 1 μM CaCYP51 (all
azoles) or 0.25 μM Δ60HsCYP51 (5d, 5 f, 12c and fluconazole) or 0.4 μM Δ60HsCYP51 (posaconazole, voriconazole, itraconazole and ketoconazole). [a] See
Figure S4.
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The novel short derivatives (5) and extended derivatives
(12) with MIC<16 μg/mL and the standard, fluconazole, were
then evaluated for CaCYP51 binding affinity (Kd) by progres-
sively titrating against CaCYP51. There were no signs of
compound insolubility (visible or rising background absorb-
ance) during the ligand titrations. Binding saturation curves
were constructed from the absorbance difference (ΔApeak-trough)
derived from the difference spectra against the antifungal
concentration for CaCYP51,[33] enabling a direct comparison of
binding type and affinity of novel compounds compared to
fluconazole and posaconazole. Type II difference binding
spectra were observed for all compounds titrated against
CaCYP51 (Figure S2 and Figure 4) indicating the direct coordi-
nation of the imidazole or triazole nitrogen atom as the sixth
axial ligand with the haem ferric ion of CaCYP51. Titration of
5d, 5f, 12c, and fluconazole with Δ60HsCYP51 also gave type II
difference binding spectra, albeit the intensity (ΔA) obtained
with 12c and fluconazole was smaller than the other two azoles
(Figure 4).
The rearranged Morrison equation[34] gave the best fit to the
ligand saturation curves against CaCYP51 (Figure 5) indicating
the selected compounds bound tightly to the purified CaCYP51
protein in free solution. Likewise the rearranged Morrison
equation[34] gave the best fit for binding 5d and 5f to
Δ60HsCYP51, thus indicating tight binding in free solution
(Figure 5). However, the Michaelis-Menten equation best fit the
binding of 12c and fluconazole to Δ60-HsCYP51, indicating the
binding was less tight (Figure 5). Previously Δ60HsCYP51 was
shown to behave near identically to the full length HsCYP51 in
terms of azole binding properties.[21]
In the short series tightest binding was observed for the
chloro derivative 5d (R1=4-Cl, R2=Cl, Kd 17�5 nM), which was
slightly better than fluconazole (Kd=41�13 nM). Good binding
affinity was also observed for other chloro derivatives 5c (R1=
4-Cl, R2=H), 5f (R1=2,4-diCl, R2=Cl) and the 4-methoxy
derivative 5 i (R1=4-OCH3, R2=H) with Kd of 60�4, 62�17 and
55�10 nM, respectively. In the extended series, the halide
derivatives 12b (R1=4-F, Kd 55�27 nM) and 12c (R
1=4-Cl, Kd
43�18 nM) showed good binding affinity comparable with
fluconazole. The Morrison equation gave estimates of Kappi from
the inhibition profiles with CaCYP51 of 160, 200 and 110 nM for
compounds 5d, 5f and 12c, respectively, compared with 30 nM
for fluconazole, confirming all four compounds bound tightly to
CaCYP51.
Both 5d and 5f bound tightly to Δ60HsCYP51 in free
solution with Kd values of 45 and 74 nM, respectively, whilst
binding of 12c was less tight and more variable with a mean Kd
of 923�509 nM (n=6; Table 5). Therefore, selectivity for
CaCYP51 over the human homologue based on Kd values was
poor for compounds 5d and 5f at 2.6- and 1.2-fold,
respectively. However, selectivity of compound 12c was higher
at 21.5-fold and was higher than posaconazole (4.7-fold) and
higher than previously observed with itraconazole and ketoco-
nazole (Table 5). However, the selectivity of compound 12c
based on Kd values was still substantially lower than those
observed for voriconazole (229-fold) and fluconazole (938-fold).
STEROL profiles
C. albicans strains (CA14 and SC5314) were grown in MOPS
buffered RPMI in the presence of DMSO (untreated) or DMSO
and antifungal (at half the MIC) for 18 hours, at 37 °C. Sterols
were then extracted and analysed by GC-MS and sterol profiles
(% of the total sterol extracted) were determined (Table 6).
The sterol profiles showed an accumulation of 14α-meth-
ylated sterols in both C. albicans strains treated with flucona-
zole, 5d, 5f and 12c. This confirms that the mechanism of
Figure 4. Azole binding difference spectra. Type II difference spectra
obtained during the progressive titration of 3 μM native CaCYP51 and
Δ60HsCYP51 with compounds 5d, 5f, 12c, fluconazole and posaconazole
are shown. Each azole titration was performed in triplicate, although only
one replicate is shown. The ligand saturation curves for these difference
spectra are shown in Figure 5.
Figure 5. CYP51 azole saturation curves. Ligand binding saturation curves
derived from the type II difference spectra in Figure 4 are shown for
compounds 5d (*), 5f (*), 12c (*), fluconazole (*) and posaconazole (*) with
3 μM native CYP51 protein. Each azole titration was performed in triplicate
although only one replicate is shown.
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action of 5d, 5f and 12c, like fluconazole, is the inhibition of
sterol 14α-demethylase (CYP51). The accumulation of 14α-
methylated sterols in the fungal membrane inhibits the growth
of the C. albicans. In particular, the accumulation of 14α-methyl
ergosta-8,24(28)-dien-3,6-diol is believed to disrupt the fungal
membrane in Candida, resulting in growth inhibition. Impor-
tantly, treatment with 0.06 μg/mL 5d resulted in a much higher
accumulation of the “diol” sterol and concomitant depletion of
ergosterol, indicating that 5d is more effective at inhibiting
CYP51 activity than fluconazole.
Molecular modelling
To investigate the binding modes of the short (5) and extended
(12) azole derivatives, molecular dynamics simulations were run
for 100 ns using the CaCYP51 crystal structure (PDB ID: 5FSA[22])
and representative short (5f) and extended (12c) azole
derivative complexes, generated by using Molecular Operating
Environment (MOE),[35] and compared with fluconazole by using
the Desmond programme of Maestro.[36] All the compounds
formed a coordination interaction between the imidazole or
triazole N and the haem Fe.
Different binding profiles were observed in the wild-type
CaCYP51 for the short derivatives (5) with a preference for the
(R)-enantiomers to form additional binding interactions within
the ligand binding site, specifically water mediated H-bonding
interactions with His310 and Tyr132 and the amide heteroa-
toms, and hydrophobic interactions with Tyr118, Met508 and
Phe126 (e.g., 5f, Figure 6), compared with fluconazole inter-
actions that form π-π stacking interactions with Tyr118 and
triazole ring and water mediated H-bonding interactions with
Tyr132 and Ser378 and the hydroxy group and the heteroatom
of the triazole ring respectively. The S enantiomers interacted
Table 6. Sterol composition (% of total sterols) of untreated and treated wild-type C. albicans strains.
Sterol composition [%]
Untreated (DMSO only) Fluconazole 0.06 [μg/mL] 5d 0.06 [μg/mL] 5f 0.015 [μg/mL] 12c 0.5 [μg/mL]
CA14 SC5314 CA14 SC5314 CA14 SC5314 CA14 SC5314 CA14 SC5314
ergosterol 76.9�3.8 77.2�3.8 63.8�3.4 72.8�3.3 7.8�6.5 2.7�2.3 4.3�0.5 9.1�5.5 3.5�1.3 24.9�5.5
diol[a] 0.2�0.4 8.2�6.0 17.6�7.1 7.5�4.6 11.7�1.4 9.2�1.2 7.2�5.2
lanosterol 3.8�0.6 5.2�5.0 19.6�1.5 14.5�1.7 40.4�2.2 41.0�5.5 43.6�1.8 38.6�3.6 43.6�1.5 34.5�2.9
eburicol 0.4�0.3 8.5�1.0 4.0�0.4 26.4�5.0 20.5�4.4 26.1�0.1 21.0�3.3 22.4�1.1 14.0�3.5
total 14α-methylated sterols 3.8 5.6 31.4 22.2 90.0 95.8 77.2 89.3 93.3 70.6
[a] 14α-Methyl ergosta-8,24(28)-dien-3,6-diol.
Figure 6. A schematic of detailed ligand atom interactions of fluconazole and representative (R)-enantiomers of short derivative 5f and extended derivative
12c with the protein residues of wild-type CaCYP51 active site. Interactions that occur more than 30.0% of the simulation time in the selected trajectory (0
through 100 ns) are shown.
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primarily via hydrophic interactions, positioned to form π-π
stacking with Tyr118 and hydrophobic interactions with
Phe126.
The R enantiomers of the extended compounds showed
preferential binding with H-bonding interactions between the
sulfonamide group and Ser378 and His377, while the amide NH
formed a water mediated interaction with Leu121. The three
benzene rings formed π-π stacking interactions with Phe126,
Tyr118 and Phe380 (e.g., 12c, Figure 6). The S enantiomer
formed H-bonding interaction between the sulfonamide and
Ser378 and the amide formed a water mediated interaction
with Tyr132.
Several studies have shown that resistant C. albicans strains
that have a double mutation CYP51 are considerably more
resistant to fluconazole compared with a single mutation.[18]
Computational studies on the binding interaction of a repre-
sentative mutant strain (Y132H+K143R) with the short (5f) and
extended (12c) azole derivative complexes was performed and
compared with fluconazole.
Of note in the binding of fluconazole with the double
mutant (Y132H+K143R) CYP51 protein is the loss of haem
binding and loss of the binding interaction with Tyr132, with
the haem now forming a water mediated interaction with
Leu376 and a π–π stacking bond with Tyr118 (Figure 7). (R)-5f
retains the haem binding interaction through the imidazole
nitrogen and although the interaction with Tyr132 and the NH
of the amide is lost as a result of the Y132H mutation an
interaction is still formed but through the O of the amide and
Leu121 as well as a π–π stacking interaction with Tyr118 and
hydrophobic interactions with Ile131 and Leu376. (R)-12c also
retains the haem binding with the triazole N and importantly
retains the H-bonding interactions with His377, Ser378 and the
amide as well as an additional H-bonding interaction between
NH of sulfonamide group and Met508, in the extension arm
(Figure 7).
For the (R)-5f and (R)-12c CYP51(Y132H+K143R) com-
plexes, the mean ΔG (bind) was calculated[37] from each frame
from the point where the complex reached equilibrium to the
final frame of the MD simulation with respect to RMSD
(Figure 8).
The ΔG values indicate positioning within the mutant
(Y132H +K143R) CaCYP51 was optimal with respect to fit of the
two ligands. The (R)-12c complex, with ΔG of   69.86�
5.46 kcal/mol would appear to have better binding affinity than
(R)-5f with a ΔG of   46.35�3.73 kcal/mol; however, this ΔG
calculation does not provide information with respect to haem
binding and subsequently water mediated biotransformation.
To determine this measurement of the distance from the azole
N and the haem Fe before and after MD simulation needs to be
determined.
In the wild-type CYP51 complexes a relatively small shift is
observed after MD stimulation (Table 7); however, a more
significant shift is observed in the case of the double mutant
(Y132H+K143R) CYP51 complexes (Table 7). For fluconazole a
Figure 7. A schematic of detailed ligand atom interactions of fluconazole and representative (R)-enantiomers of short derivative 5f and extended derivative
12c with the double mutant (Y132H+K143R) CaCYP51 protein. Interactions that occur more than 30.0% of the simulation time in the selected trajectory (0–
100 ns) are shown.
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shift of 2.37 Å (pre-MD) to 4.01 Å (post-MD) reflects the loss of
haem binding (Figure 7) and might explain the reduced effect
of fluconazole against this mutant CaCYP51.[17,18] A less signifi-
cant shift, compared with fluconazole, is observed with the
(Y132H+K143R) CYP51 complexes of (R)-5f and (R)-12c from
2.39 and 2.33 Å (pre-MD) to 3.08 and 3.11 Å (post-MD),
respectively (Table 7). This shift still allows binding with the
haem, as seen in Figure 7, and the additional bonding
interactions, in particular for (R)-12c, is reflected in the ΔG
(bind) calculations (Figure 8).
The placement of the azole derivatives in comparison with
posaconazole and fluconazole in the CaCYP51 active site was
visualised using MOE. Posaconazole (Figure 9, magenta) sits in a
long hydrophobic channel with bonding primarily through
multiple hydrophobic interactions with just one H-bonding
interaction observed between Ala61 and the carbonyl oxygen
of the 1,2,4-triazol-5(4H)-one ring. The optimal placement of
fluconazole (Figure 9, cyan) was obtained after molecular
dynamics simulations and, as expected, occupies a smaller area
of the ligand binding channel compared with posaconazole
with consequently fewer binding interactions. The short azole
derivatives (5) mimic the positioning of fluconazole, whereas
the more extended derivatives (e.g., 12c, yellow, Figure 9) sit
between posaconazole and fluconazole, however importantly
they form additional binding interactions with residues in the
access channel compared with posaconazole, primarily through
the sulfonamide group and benzene rings.
Conclusion
Two series of novel azole derivatives, short and extended
derivatives, have been designed, synthesised and investigated
for CYP51 inhibitory activity, binding affinity and MIC against C.
albicans strains. The short derivatives were more potent against
the C. albicans strains (e.g., 5f, MIC<0.03 μg/mL, 12c, MIC
1 μg/mL, fluconazole 0.125 μg/mL) but both displayed compa-
rable enzyme binding and inhibition (5f Kd 62�17 nM, IC50
0.46 μM; 12c Kd 43�18 nM, IC50 0.33 μM, fluconazole Kd 41�
13 nM, IC50 0.31 μM). To determine whether any specific
physicochemical factors might account for the difference in
Figure 8. RMSD [Å] plot with respect to time in nanoseconds during 100 ns
MD stimulation of A) (R)-5 f and CYP51 (Y132H+K143R) complex and B) (R)-
12c and CYP51(Y132H+K143R) complex.
Table 7. The distance between the N-azole ring and the haem iron in the
wild type/mutant CaCYP51 active site pre and post MD.
Compd Wild type CaCYP51 [Å] (Y132H+K143R) CaCYP51 [Å]
Pre-MD Post-MD Pre-MD Post-MD
5f 2.20 2.50 2.39 3.08
12c 2.67 3.38 2.33 3.11
Fluc 2.74 2.28 2.37 4.10
Figure 9. CaCYP51-posaconazole (magenta) complex (PDB 5FSA) with pos-
aconazole positioned along the hydrophobic active site cavity and above
the haem (orange). Fluconazole (cyan) and extended derivative 12c (yellow)
are aligned after MD simulations.
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MIC, the physicochemical properties of the most promising
prepared compounds and reference antifungal agents were
calculated (Table 8). The clogP was determined using Crippen’s
fragmentation[29] the molecular weight (MW), number of H-
bond acceptors (nON), H-bond donors (nOHNH) rotatable
bonds (nrot), along with the molecular volume (MV) and
topological polar surface area (TPSA) were calculated using
Molinspiration software.[38] The number of violations (nviol) of
Lipinskys is determined from the data presented (Table 8).
The two series have a significantly increased clogP, although
still within Lipinsky range, when compared with fluconazole but
are similar to voriconazole and oteseconazole. The short series
fits between fluconazole and voriconazole, while the extended
series more closely resembles oteseconazole in all other
physicochemical properties but, unlike the clinically described
azoles, the extended series does not violate Lipinskys, showing
more optimal drug like properties. There is a considerable range
in all the physicochemical properties calculated for the clinically
used potent azole antifungals, and the only clear difference
observed with the two described series is for compound 12c,
which has two H-donors whereas all other compounds have
one H-donor.
The short series had poor selectivity for CaCYP51 over the
human homologue based on Kd values, while the selectivity of
the extended series, for example, compound 12c, was higher at
21.5-fold and was higher than posaconazole (4.7-fold) and
higher than previously observed with itraconazole and ketoco-
nazole, suggesting the extended series as optimal for further
development. The extended series is better able to fill the
binding site of CaCYP51 and forms additional binding inter-
actions (H-bonds with His377, Ser378, π–π stacking interactions
with Phe126, Tyr118 and Phe380). Computational studies would
suggest that the extended series (12) in particular may
compensate for CYP51 mutations in resistant C. albicans strains
through the formation of additional H-bonding interactions, for
example, with His277, Ser378 and Met508 in CaCYP51. The
research described here will be developed further through
computational studies to optimise binding interactions for
CaCYP51 versus HsCYP51 and “design in” selectivity of
extended azole inhibitors, while maintaining optimal drug like
properties.
Experimental Section
Chemistry
All reagents and solvents were of general purpose or analytical
grade and purchased from Sigma-Aldrich, Fisher Scientific, Fluka,
Alfa Aesar and Acros. Lanosterol and fluconazole were supplied by
Sigma-Aldrich. Ni2+-NTA agarose affinity chromatography matrix
was obtained from Qiagen. 1H and 13C NMR spectra were recorded
with a Bruker Avance DPX500 spectrometer operating at 500 and
125 MHz, with Me4Si as internal standard. Mass spectra (HRMS)
were determined by the Engineering and Physical Sciences
Research Council National Mass Spectrometry Service Centre at
Swansea University (Swansea, UK). Elemental analysis was per-
formed by MEDAC Ltd (Chobham, Surrey, UK); HPLC (Method A,
Cardiff University) was performed on a Shimadzu LC-2030C Plus
C18 Rapid Resolution 250×4.6 mm, 5 μm particle size using a 7–
10 min gradient of water/methanol 5 : 95 (Method B, University of
Bath) was performed on a Zorbax Eclipse Plus C18 Rapid Resolution
2.1×50 mm, 1.8 μm particle size using a 7.5 minute gradient
method 5 :95 water: methanol with 0.1% formic acid as additive.
Gradient column chromatography was performed with silica gel 60
(230-400 mesh; Merck) and TLC was carried out on precoated silica
plates (kiesel gel 60 F254, BDH). Compounds were visualised by
illumination under UV light (254 nm) or by the use of vanillin stain
followed by heating. Melting points were determined on an
electrothermal instrument and are uncorrected. All solvents were
dried prior to use and stored over 4 Å molecular sieves, under
nitrogen. All the compounds were�95% pure.
General procedure for the preparation of azoles (5and 12) and
alkene elimination products (6and 13). To a stirred solution of
azole (imidazole or triazole or tetrazole; 4 equiv) in dry CH3CN
(2 mL/mmol of azole) was added potassium carbonate (4 equiv),
and the mixture was heated for 1 h at 45 °C. After cooling to room
temperature, mesylate (4 or 11; 1 equiv) was added and the
reaction was heated at 70 °C for 4 h then stirred at room temper-
ature overnight. The solvent was evaporated under vacuum and
the residue was extracted with EtOAc (35 mL/mmol of mesylate),
washed with brine (3×35 mL/mmol of mesylate) and water (3×
35 mL/mmol of mesylate). The organic layer was dried (MgSO4) and
evaporated under vacuum to give the crude product, which was
purified by gradient column chromatography. Alkene (6 or 13) was
eluted first with petroleum ether/EtOAc system, followed by the
azole product (5 or 12) on changing the system to CH2Cl2/MeOH.
N-Benzyl-2-phenylacrylamide (6a, R1=R2=H). Prepared from 3-
(benzylamino)-3-oxo-2-phenylpropyl methanesulfonate (4a; 0.48 g,
1.44 mmol) and purified by petroleum ether/EtOAc gradient
column chromatography eluting with 70 :30 v/v. Product was
obtained as a white solid, yield 0.27 g (62%); m.p. 78–80 °C; TLC
(petroleum ether/EtOAc 1 :1, v/v), Rf=0.78;
1H NMR ([D6]DMSO): δ
8.74 (t, J=5.9 Hz, 1H, NH), 7.43 (m, 2H, Ar), 7.35 (m, 7H, Ar), 7.26 (m,
1H, Ar), 5.79 (s, 1H, C=CHaHb), 5.68 (s, 1H, C=CHaHb), 4.40 (d, J=
6.1 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ 168.70 (C, C=O), 145.65
(C, C=CH2), 140.07 (C, Ar), 137.18 (C, Ar), 128.79 (2×CH, Ar), 128.77
(2×CH, Ar), 128.57 (CH, Ar), 127.61 (2×CH, Ar), 127.52 (2×CH, Ar),
127.21 (CH, Ar), 118.17 (C=CH2), 42.81 (NHCH2); HRMS (ESI), m/z
calcd for C16H16NO ([M+H]
+), 238.1257; found: 238.1226.
N-(4-Fluorobenzyl)-3-(1H-imidazol-1-yl)-2-phenylpropanamide
(5b, R1=4-F, R2=H) and N-(4-fluorobenzyl)-2-phenylacrylamide
(6b, R1=4-F, R2=H). Prepared from 3-((4-fluorobenzyl)amino)-3-
oxo-2-phenylpropyl methanesulfonate (4b; 0.70 g, 1.98 mmol) and
purified by gradient column chromatography eluting the alkene
(6b) with petroleum ether/EtOAc 70 :30 v/v, followed by the
imidazole (5b) with CH2Cl2/MeOH 90 :10 v/v. N-(4-Fluorobenzyl)-3-
(1H-imidazol-1-yl)-2-phenylpropanamide (5b) was obtained as a
Table 8. Physiocochemical properties of selected derivatives and clinical
antifungal agents.
Cmpd MW clogP nON/
nOHNH
nrot MV
[Å3]
TPSA
[Å  2]
nviol
5d 374.264 4.1 4/1 6 316.96 46.92 0
5f 408.709 4.66 4/1 9 414.51 46.92 0
12c 495.981 3.46 8/2 9 414.51 105.98 0
fluconazole 306.271 0.87 7/1 5 248.96 81.66 0
voriconazole 349.311 2.59 6/1 5 285.11 76.73 0
itraconazole 705.633 7.07 12/1 11 607.90 104.73 3
posaconazole 700.777 5.74 12/1 12 623.35 115.72 3
oteseconazole 527.394 5.2 7/1 9 401.65 85.96 2
nON=H-bond acceptor; nOHNH=H-bond donor; nrot=number of rotatable
bonds; MV=molecular volume; TPSA= topological polar surface area;
nviol=number of Lipinsky violations (violations are italicised).
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cream solid, yield 0.22 g (34%); m.p. 100–102 °C; TLC (petroleum
ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR ([D6]DMSO): δ 8.61 (t, J=
5.9 Hz, 1H, NH), 7.53 (brs, 1H, imid), 7.40 (d, J=7.05 Hz, 2H, Ar), 7.34
(t, J=7.4 Hz, 2H, Ar), 7.29 (t, J=7.2 Hz, 1H, Ar), 7.11 (brs, 1H, imid),
7.03 (m, 4H, Ar), 6.88 (brs, 1H, imid), 4.63 (dd, J=9.7, 13.4 Hz, 1H,
CHCHaHb), 4.29 (dd, J=6.4, 15.3 Hz, 1H, NHCHaHb), 4.24 (dd, J=
5.7, 13.4 Hz, CHCHaHb), 4.10 (dd, J=5.5, 15.2 Hz, NHCHaHb), 4.02
(dd, J=5.8, 9.6 Hz, CHCHaHb); 13C NMR ([D6]DMSO): δ 171.06 (C,
C=O), 162.52 and 160.60 (C,C  F), 137.94 (C, Ar), 135.63 (C, Ar),
130.15 (CH, imid), 130.09 (CH, imid), 129.38 (CH, Ar), 129.32 (CH, Ar),
128.93 (2×CH, Ar), 128.27 (2×CH, Ar), 127.86 (CH, Ar), 115.66 (CH,
imid), 115.40 (CH, Ar), 115.23 (CH, Ar), 53.33 (CHCH2imid), 48.88
(CHCH2imid), 41.80 (NHCH2); LRMS (ES, m/z): 324.15 [C19H18FN3O+
H]+; HRMS (ESI), m/z calcd for C19H19FN3O ([M+H]
+), 324.1507;
found: 324.1507; HPLC (Method A): 98.0%, tR=4.87 min. N-(4-
Fluorobenzyl)-2-phenylacrylamide (6b) was obtained as a white solid,
yield 0.25 g (39%); m.p. 108–110 °C; TLC (petroleum ether/EtOAc
1 :1 v/v); Rf=0.79;
1H NMR ([D6]DMSO): δ 8.74 (t, J=5.4 Hz, 1H, NH),
7.43 (d, J=7.7 Hz, 2H, Ar), 7.36 (m, 5H, Ar), 7.17 (t, J=8.9 Hz, 2H, Ar),
5.79 (s, 1H, C=CHaHb), 5.69 (s, 1H, C=CHaHb), 4.38 (d, J=6.0 Hz, 2H,
NHCH2);
13C NMR ([D6]DMSO): δ 168.68 (C, C=O), 162.60 and 160.67
(C, C  F), 145.60 (C, Ar), 137.16 (C, Ar), 136.27 (C, C=CH2), 129.67 (CH,
Ar), 129.61 (CH, Ar), 128.79 (2×CH, Ar), 128.58 (CH, Ar), 127.53 (2×
CH, Ar), 118.29 (C=CH2), 115.57 (CH, Ar), 115.40 (CH, Ar), 42.16
(NHCH2); elemental analysis calcd (%) for C16H14FNO (255.2911): C
75.28, H 5.53, N 5.48; found: C 75.34, H 5.32, N 5.55.
N-(4-Chlorobenzyl)-3-(1H-imidazol-1-yl)-2-phenylpropanamide
(5c, R1=4-Cl, R2=H). Prepared from 3-((4-chlorobenzyl)amino)-3-
oxo-2-phenylpropyl methanesulfonate (4c; 0.38 g, 1.0 mmol) and
purified by gradient column chromatography eluting the imidazole
(5c) with CH2Cl2/MeOH 90 :10 v/v. Product was obtained as a cream
solid, yield 0.20 g (56%); m.p. 136–138 °C; TLC (petroleum ether/
EtOAc 1 :1 v/v), Rf=0.0;
1H NMR ([D6]DMSO): δ 8.67 (t, J=5.8 Hz, 1H,
NH), 7.52 (s, 1H, imid), 7.40 (m, 2H, Ar), 7.35 (m, 2H, Ar), 7.29 (m, 3H,
Ar), 7.11 (s, 1H, imid), 6.96 (d, J=8.2 Hz, 2H, Ar), 6.88 (s, 1H, imid),
4.63 (dd, J=9.9, 13.3 Hz, 1H, CHCHaHb), 4.30 (dd, J=6.4, 15.5 Hz,
1H, NHCHaHb), 4.23 (dd, J=5.6, 13.4 Hz, CHCHaHb), 4.10 (dd, J=
5.4, 15.5 Hz, NHCHaHb), 4.03 (dd, J=5.7, 9.7 Hz, CHCHaHb); 13C NMR
([D6]DMSO): δ 171.2 (C, C=O), 138.5 (C, Ar), 137.9 (C, Ar), 131.7 (C,
C  Cl), 129.2 (3×CH, Ar (2) and imid (1)), 129.0 (2×CH, Ar), 128.6 (3×
CH, Ar (2) and imid (1)), 128.3 (2×CH, Ar), 127.9 (CH, Ar), 120.0 (CH,
imid), 53.3 (CHCH2imid), 50.8 (CHCH2imid), 41.8 (NHCH2); elemental
analysis calcd (%) for C19H18ClN3O·0.1H2O (341.6215): C 66.80, H
5.37, N 12.30; found: C 66.44, H 5.07, N 12.39; HPLC (Method A):
99.0%, tR=4.94 min.
N-(4-Chlorobenzyl)-2-(4-chlorophenyl)-3(1H-imidazol-1-yl)propa-
namide (5d, R1=R2=4-Cl) and N-(4-chlorobenzyl)-2-(4-chloro-
phenyl)acrylamide (6d, R1=R2=4-Cl). Prepared from 3-((4-chlor-
obenzyl)amino)-2-(4-chlorophenyl)-3-oxopropyl methanesulfonate
(4d; 0.44 g, 1.09 mmol) and purified by gradient column chroma-
tography eluting the alkene (6d) with petroleum ether/EtOAc
70 :30 v/v, followed by the imidazole (5d) with CH2Cl2/MeOH 90 :10
v/v. Imidazole 5d was further purified by recrystallization from
CH3CN. N-(4-Chlorobenzyl)-2-(4-chlorophenyl)-3(1H-imidazol-1-yl)
propanamide (5d) was obtained as a brown solid, yield 0.11 g
(26%); m.p. 160–162 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=
0.0; 1H NMR ([D6]DMSO): δ 8.66 (t, J=5.9 Hz, 1H, NH), 7.50 (s, 1H,
imid.), 7.40 (m, 4H, Ar), 7.29 (d, J=8.5 Hz, 2H, Ar), 7.09 (s, 1H, imid.),
6.98 (d, J=8.5 Hz, 2H, Ar), 6.86 (s, 1H, imid.), 4.59 (dd, J=9.4,
13.5 Hz, 1H, CHCHaHb), 4.29 (dd, J=6.4, 15.4 Hz, 1H, NHCHaHb),
4.24 (dd, J=6.1, 13.5 Hz, 1H, CHCHaHb), 4.10 (dd, J=5.4, 15.5 Hz,
1H, NHCHaHb), 4.05 (dd, J=6.1, 9.4 Hz, 1H, CHCHaHb); 13C NMR
([D6]DMSO): δ 170.78 (C, C=O), 138.41 (C, Ar), 138.06 (CH, imid),
136.78 (C, Ar), 132.59 (C, C  Cl), 131.75 (C, C  Cl), 130.16 (2×CH, Ar),
129.23 (2×CH, Ar), 128.92 (2×CH, Ar), 128.68 (CH, imid), 128.57 (2×
CH, Ar), 119.95 (CH, imid), 52.59 (CHCH2-imid), 48.66 (CHCH2imid),
41.85 (NHCH2); elemental analysis calcd (%) for C19H17Cl2N3O
(374.2688): C 60.97, H 4.58, N 11.22; found: C 60.99, H 4.50, N 11.20;
HPLC (Method A): 96.3%, tR=2.53 min. N-(4-Chlorobenzyl)-2-(4-
chlorophenyl)acrylamide (6d) was obtained as an off-white solid,
yield 0.09 g (22%); m.p. 108–110 °C; TLC (petroleum ether/EtOAc
1 :1 v/v); Rf=0.73;
1H NMR ([D6]DMSO): δ 8.80 (t, J=5.9 Hz, 1H, NH),
7.45 (m, 4H, Ar), 7.41 (d, J=8.5 Hz, 2H, Ar), 7.33 (d, J=8.5 Hz, 2H,
Ar), 5.84 (s, 1H, C=CHaHb), 5.76 (s, 1H, C=CHaHb), 4.37 (d, J=6.1 Hz,
2H, NHCH2);
13C NMR ([D6]DMSO): δ 168.27 (C, C=O), 144.20 (C,
C=CH2), 139.02 (C, Ar), 135.98 (C, C  Cl), 133.27 (C, C  Cl), 131.80 (C,
Ar), 129.55 (2×CH, Ar), 129.46 (2×CH, Ar), 128.80 (2×CH, Ar),
128.74 (2×CH, Ar), 119.40 (C=CH2), 42.26 (NHCH2); elemental
analysis calcd (%) for C16H13Cl2NO (306.1908): C 62.76, H 4.28, N
4.57; found: C 63.07, H 4.30, N 4.61.
N-(2,4-Dichlorobenzyl)-3-(1H-imidazol-1-yl)-2-phenylpropana-
mide (5e, R1=2,4-Cl, R2=H) and N-(2,4-dichlorobenzyl)-2-phenyl-
acrylamide (6e, R1=2,4-Cl, R2=H). Prepared from 3-((2,4-dichlor-
obenzyl)amino)-3-oxo-2-phenylpropyl methanesulfonate (4e; 0.5 g,
1.24 mmol) and purified by gradient column chromatography
eluting the alkene (6e) with petroleum ether/EtOAc 80 :20 v/v,
followed by the imidazole (5e) with CH2Cl2/MeOH 90 :10 v/v. N-(2,4-
Dichlorobenzyl)-3-(1H-imidazol-1-yl)-2-phenylpropanamide (5e) was
obtained as a cream solid, yield 0.34 g (74%); m.p. 55–57 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR ([D6]DMSO): δ
8.68 (t, J=5.8 Hz, 1H, NH), 7.56 (d, J=2.1 Hz, 1H, Ar), 7.54 (brs, 1H,
imid), 7.41 (d, J=7.2 Hz, 2H, Ar), 7.36 (t, J=7.4 Hz, 2H, Ar), 7.30 (t,
J=7.2 Hz, 1H, Ar), 7.23 (dd, J=2.1, 8.4 Hz, 1H, Ar), 7.13 (brs, 1H,
imid), 6.90 (brs, 1H, imid), 6.75 (d, J=8.4 Hz, 1H, Ar), 4.63 (dd, J=
9.8, 13.4 Hz, 1H, CHCHaHb), 4.31 (dd, J=6.2, 16.0 Hz, 1H,
NHCHaHb), 4.23 (dd, J=5.7, 13.4 Hz, 1H, CHCHaHb), 4.16 (dd, J=
5.4, 16.0 Hz, 1H, NHCHaHb), 4.10 (dd, J=5.7, 9.8 Hz, 1H, CHCHaHb));
13C NMR ([D6]DMSO): δ 171.32 (C, C=O), 137.72 (C, Ar), 135.52 (C,
Ar), 133.34 (C, C  Cl), 132.63 (C, C  Cl), 130.12 (2×CH, Ar (1) and imid
(1)), 128.97 (3×CH, Ar), 128.30 (2×CH, Ar), 127.94 (2×CH, Ar (1) and
imid (1)), 127.51 (2×CH, Ar (1) and imid (1)), 53.21 (CHCH2imid),
48.86 (CHCH2imid), 40.01 (NHCH2); elemental analysis calcd (%) for
C19H17Cl2N3O·0.2H2O (377.87184): C 60.39, H 4.64, N 11.12; found: C
60.04, H 4.46, N 10.85; HPLC (Method A): 96.20%, tR=3.20 min. N-
(2,4-Dichlorobenzyl)-2-phenylacrylamide (6e) was obtained as a
cream solid, yield 0.05 g (11%); m.p. 66–68 °C; TLC (petroleum
ether/EtOAc 1 :1 v/v), Rf=0.85;
1H NMR ([D6]DMSO): δ 8.76 (t, J=
5.8 Hz, 1H, NH), 7.63 (d, J=2.1 Hz, 1H, Ar), 7.47 (m, 3H, Ar), 7.34 (m,
5H, Ar), 5.83 (s, 1H, C=CHaHb), 5.75 (s, 1H, C=CHaHb), 4.44 (d, J=
5.9 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ 168.87 (C, C=O), 145.33
(C, C=CH2), 137.04 (C, Ar), 136.02 (C, C  Cl), 133.41 (C, C  Cl), 132.67
(C, Ar), 130.58 (CH, Ar), 129.06 (CH, Ar), 128.82 (2×CH, Ar), 128.63
(CH, Ar), 127.85 (CH, Ar), 127.58 (2×CH, Ar), 118.73 (C=CH2), 40.01
(NHCH2); LRMS (ESI, m/z): 308.0417 [C16H13
37Cl2NO+H]
+, 306.0447
[C16H13
35Cl2NO+H]
+, 158.98 [C7H5
35Cl2]
+; HRMS (ES), m/z calcd for
C16H14
35Cl2NO ([M+H]
+), 306.0447; found: 306.0449; and calcd for
C16H14
37Cl2NO ([M+H]
+), 308.0417; found: 308.0418.
2-(4-Chlorophenyl)-N-(2,4-dichlorobenzyl)-3-(1H-imidazol-1-yl)
propanamide (5 f, R1=2,4-diCl, R2=Cl) and 2-(4-chlorophenyl)-N-
(2,4-dichlorobenzyl)acrylamide (6 f, R1=2,4-diCl, R2=Cl). Prepared
from 2-(4-chlorophenyl)-3-((2,4-dichlorobenzyl)amino)-3-oxopropyl
methanesulfonate (4f; 0.54 g, 1.24 mmoL) and purified by gradient
column chromatography eluting the alkene (6e) with petroleum
ether/EtOAc 60 :40 v/v, followed by the imidazole (5e) with CH2Cl2/
MeOH 90 :10 v/v. 2-(4-Chlorophenyl)-N-(2,4-dichlorobenzyl)-3-(1H-
imidazol-1-yl)propanamide (5 f) was obtained as a white solid, yield
0.21 g (41%); m.p. 148–150 °C; TLC (petroleum ether/EtOAc 1 :1 v/
v); Rf=0.0;
1H NMR ([D6]DMSO): δ 8.69 (t, J=5.7 Hz, 1H, NH), 7.56 (d,
J=2.2 Hz, 1H, Ar), 7.50 (brs, 1H, imid), 7.41 (m, 4H, Ar), 7.26 (dd, J=
2.1, 8.3 Hz, 1H, Ar), 7.10 (brs, 1H, imid), 6.88 (brs, 1H, imid), 6.79 (d,
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J=8.4 Hz, 1H, Ar), 4.58 (dd, J=9.5, 13.4 Hz, 1H, CHCHaHb), 4.30 (dd,
J=6.1, 15.9 Hz, 1H, NHCHaHb), 4.23 (dd, J=6.0, 13.5 Hz, 1H,
CHCHaHb), 4.16 (dd, J=5.5, 15.9 Hz, 1H, NHCHaHb), 4.10 (dd, J=
6.0, 9.5 Hz, 1H, CHCHaHb); 13C NMR ([D6]DMSO): δ 170.96 (C, C=O),
138.02 (CH, imid), 136.64 (C, Ar), 135.41 (C, Ar), 133.40 (C, C  Cl),
132,69 (C, C  Cl), 132.63 (C, C  Cl), 130.24 (CH, Ar), 130.19 (2×CH,
Ar), 129.00 (CH, Ar), 128.94 (2×CH, Ar), 128.74 (CH, imid), 127.57
(CH, Ar), 119.92 (CH, imidazole), 52.47 (CHCH2), 48.68 (CHCH2), 40.58
(NHCH2); HRMS (ESI), m/z calcd for C19H17Cl3N3O ([M+H]
+),
408.0438; found: 408.0432; HPLC (Method A): 99.6%, tR=4.56 min.
2-(4-Chlorophenyl)-N-(2,4-dichlorobenzyl)acrylamide (6 f) was ob-
tained as a white solid, yield 0.19 g (37%); m.p. 104–106 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v); Rf=0.87;
1H NMR ([D6]DMSO): δ
8.81 (t, J=5.8 Hz, 1H, NH), 7.62 (d, J=2.1 Hz, 1H, Ar), 7.46 (dd, J=
8.9, 16.3 Hz, 5H, Ar), 7.39 (d, J=8.3 Hz, 1H, Ar), 5.88 (s, 1H,
C=CHaHb), 5.80 (s, 1H, C=CHaHb), 4.43 (d, J=5.9 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ 168.43 (C, C=O), 143.97 (C, C=CH2), 135.91
(C, Ar), 135.88 (C, C  Cl), 133.41 (C, C  Cl), 133.30 (C, C  Cl), 132.69 (C,
Ar), 130.60 (CH, Ar), 129.49 (2×CH, Ar), 129.07 (CH, Ar), 128.81 (2×
CH, Ar), 127.86 (CH, Ar), 119.69 (C=CH2), 40.49 (NHCH2); HRMS (ESI),
m/z calcd for C16H12Cl3NONa ([M+Na]
+), 361.9882; found: 361.9880.
3-(1H-Imidazol-1-yl)-N-(4-methylbenzyl)-2-phenylpropanamide
(5g, R1=4-CH3, R
2=H) and N-(4-methylbenzyl)-2-phenylacryla-
mide (6g, R1=4-CH3, R2=H). Prepared from 3-((4-methylbenzyl)
amino)-3-oxo-2-phenylpropyl methanesulfonate (4g; 0.7 g,
2.0 mmol) and purified by gradient column chromatography
eluting the alkene (6g) with petroleum ether/EtOAc 70 :30 v/v,
followed by the imidazole (5g) with CH2Cl2/MeOH 90 :10 v/v. 3-(1H-
Imidazol-1-yl)-N-(4-methylbenzyl)-2-phenylpropanamide (5g) was ob-
tained as a cream solid, yield 0.03 g (5%); m.p. 134–136 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v), Rf=0.0;
1H NMR ([D6]acetone): δ
7.72 (brs, 1H, NH), 7.52 (brs, 1H, imid.), 7.44 (d, J=7.0 Hz, 2H, Ar),
7.32 (m, 3H, Ar), 7.11 (brs, 1H, imid.), 7.04 (d, J=7.9 Hz, 2H, Ar), 6.95
(d, J=8.0 Hz, 2H, Ar), 6.91 (brs, 1H, imid.), 4.76 (dd, J=9.3, 13.6 Hz,
1H, CHCHaHb), 4.37 (dd, J=6.2, 14.8 Hz, 1H, NHCHaHb), 4.28 (dd,
J=5.7, 13.6 Hz, 1H, CHCHaHb), 4.23 (dd, J=5.6, 15.0 Hz, 1H,
NHCHaHb), 4.09 (dd, J=5.7, 9.3 Hz, 1H, CHCHaHb), 2.27 (s, 3H, CH3);
13C NMR ([D6]acetone): δ 170.50 (C, C=O), 137.77 (C, Ar), 136.18 (C,
Ar), 136.01 (C, Ar), 128.80 (2×CH, Ar), 128.55 (3×CH, Ar (2) and imid
(1)), 128.39 (CH, imid), 127.98 (3×CH, Ar (2) and imid (1)), 127.48
(2×CH, Ar), 127.18 (2×CH, Ar), 54.00 (CHCH2imid), 49.20
(CHCH2imid), 42.24 (NHCH2) 20.10 (CH3); HRMS (ESI), m/z calcd for
C20H22N3O ([M+H]
+), 320.1786; found: 320.1757; HPLC (Method A):
95.5%, tR=2.49 min. N-(4-Methylbenzyl)-2-phenylacrylamide (6g)
was obtained as an off-white solid, yield 0.38 g (59%); m.p. 92–
94 °C; TLC (petroleum ether/EtOAc 1 :1 v/v), Rf=0.78; 1H NMR ([D6]
DMSO): δ 8.69 (t, J=6.0 Hz, 1H, NH), 7.43 (m, 2H, Ar), 7.35 (m, 3H,
Ar), 7.20 (d, J=8.0 Hz, 2H, Ar), 7.15 (d, J=7.9 Hz, 2H, Ar), 5.78 (s, 1H,
C=CHaHb), 5.66 (s, 1H, C=CHaHb), 4.35 (d, J=6.1 Hz, 2H, NHCH2),
2.29 (s, 3H, CH3);
13C NMR ([D6]DMSO): δ 168.63 (C, C=O), 145.68 (C,
C=CH2), 137.19 (C, Ar), 137.04 (C, Ar), 136.23 (C, Ar), 129.31 (2×CH,
Ar),128.78 (2×CH, Ar), 128.55 (CH, Ar), 127.63 (2×CH, Ar), 127.50
(2×CH, Ar), 118.06 (C=CH2), 42.54 (NHCH2), 21.14 (CH3); elemental
analysis calcd (%) for C17H17NO (251.3274): C 81.24, H 6.82, N 5.57;
found: C 81.35, H 7.06, N 5.53.
3-(1H-Imidazol-1-yl)-2-phenyl-N-(4-(trifluoromethyl)benzyl)propa-
namide (5h, R1=4-CF3, R2=H) and 2-phenyl-N-(4-(trifluorometh-
yl)benzyl)acrylamide (6h, R1=4-CF3, R2=H). Prepared from 3-oxo-
2-phenyl-3-((4-(trifluoromethyl)benzyl)amino)propyl methanesulfo-
nate (4h; 0.58 g, 1.44 mmol) and purified by gradient column
chromatography eluting the alkene (6h) with petroleum ether/
EtOAc 70 :30 v/v, followed by the imidazole (5h) with CH2Cl2/MeOH
90 :10 v/v. 3-(1H-Imidazol-1-yl)-N-(4-(trifluoromethyl)benzyl)-2-phenyl-
propanamide (5h) was obtained as a brown amorphous solid, yield
0.02 g (4%); TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR
([D6]acetone): δ 7.87 (brs, 1H, NH), 7.50 (m, 4H, Ar (3) and imid. (1)),
7.33 (m, 2H, Ar (1) and imid. (1)), 7.21 (m, 4H, Ar (3) and imid. (1)),
7.11 (m, 2H, Ar), 4.67 (dd, J=9.8, 12.8 Hz, 1H, CHCHaHb), 4.38 (dd,
J=6.2, 15.6 Hz, 1H, NHCHaHb), 4.22 (d, J=5.3 Hz, 1H, CHCHaHb),
4.20 (t, J=5.2 Hz, 1H, NHCHaHb), 4.05 (dd, J=5.3, 8.9 Hz, 1H,
CHCHaHb); 13C NMR ([D6]acetone): δ 170.85 (C, C=O), 143.94 (C, Ar),
137.47 (C, Ar), 128.64 (3×CH, Ar), 128.31 (CH, imid), 128.28 (C, Ar),
128.25 (CH, imid), 127.99 (3×CH, Ar), 127.63 (CH, Ar), 127.60 (2×CH,
Ar), 127.49 (CH, imid), 125.07 & 125.04 (CF3), 53.82 (CHCH2imid),
49.89 (CHCH2imid), 42.03 (NHCH2);
19F NMR ([D6]acetone): δ   62.87;
HRMS (ESI), m/z calcd for C20H19F3N3O ([M+H]
+), 374.1506; found:
374.1475; HPLC (Method A): 97.7%, tR=3.47 min. 2-Phenyl-N-(4-
(trifluoromethyl)benzyl)acrylamide (6h) was obtained as an off-white
solid, yield 0.32 g (59%); m.p. 88–90 °C; TLC (petroleum ether/EtOAc
1 :1 v/v); Rf=0.74;
1H NMR ([D6]DMSO): δ 8.83 (t, J=6.0 Hz, 1H, NH),
7.72 (d, J=8.1 Hz, 2H, Ar), 7.54 (d, J=8.0 Hz, 2H, Ar), 7.43 (d, J=
6.8 Hz, 2H, Ar), 7.36 (m, 3H, Ar), 5.81 (s, 1H, C=CHaHb), 5.73 (s, 1H,
C=CHaHb), 4.48 (d, J=6.1 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ
168.81 (C, C=O), 145.46 (C, =C=), 144.97 (C, Ar), 137.10 (C, Ar),
128.81 (2×CH, Ar), 128.61 (CH, Ar), 128.30 (3×CH, Ar), 127.80 (C,
Ar), 127.57 (3×CH, Ar), 125.69 & 125.66 (CF3), 118.60 (C=CH2), 42.55
(NHCH2);
19F NMR ([D6]DMSO): δ   60.78; elemental analysis calcd
(%) for C17H14F3NO·0.1H2O (307.10042): C 66.49, H 4.66, N 4.56;
found: C 66.43, H 4.75, N 4.48.
3-(1H-Imidazol-1-yl)-N-(4-methoxybenzyl)-2-phenylpropanamide
(5 i, R1=4-OCH3, R2=H) and N-(4-methoxybenzyl)-2-phenylacryla-
mide (6 i, R1=4-OCH3, R2=H). Prepared from 3-((4-methoxybenzyl)
amino)-3-oxo-2-phenylpropyl methanesulfonate (4 i; 0.67 g,
1.85 mmol) and purified by gradient column chromatography
eluting the alkene (6 i) with petroleum ether/EtOAc 60 :40 v/v,
followed by the imidazole (5 i) with CH2Cl2/MeOH 90 :10 v/v. 3-(1H-
Imidazol-1-yl)-N-(4-methoxybenzyl)-2-phenylpropanamide (5 i) was
obtained as a brown solid, yield 0.17 g (27%); m.p. 102–104 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR ([D6]DMSO): δ
8.52 (t, J=5.8 Hz, 1H, NH), 7.53 (brs, 1H, imid), 7.39 (d, J=7.2 Hz,
2H, Ar), 7.34 (t, J=7.4 Hz, 2H, Ar), 7.28 (t, J=7.2 Hz, 1H, Ar), 7.09
(brs, 1H, imid), 6.93 (d, J=8.6 Hz, 2H, Ar), 6.87 (brs, 1H, imid), 6.79
(d, J=8.6 Hz, 1H, Ar), 4.62 (dd, J=9.6, 13.4 Hz, 1H, CHCHaHb), 4.24
(φt, J=5.6, 4.3 Hz, 1H, NHCHaHb), 4.22 (t, J=5.8 Hz, 1H, CHCHaHb),
4.06 (dd, J=5.4, 14.9 Hz, 1H, NHCHaHb), 4.00 (dd, J=5.8, 9.5 Hz, 1H,
CHCHaHb), 3.71 (s, 3H, CH3);
13C NMR ([D6]DMSO): δ 170.89 (C, C=O),
158.64 (C, C-OCH3), 138.05 (C, Ar), 131.30 (C, Ar), 128.90 (2×CH, Ar
(1) and imid (1)), 128.77 (2×CH, Ar (1) and imid (1)), 128.28 (2×CH,
Ar (1) and imid (1)), 127.81 (CH, Ar), 114.05 (2×CH, Ar), 55.52
(OCH3), 53.31 (CHCH2imid), 48.91 (CHCH2imid), 41.99 (NHCH2); LRMS
(ES+TOF, m/z): 336.17 [C20H21N3O2+H]
+; HRMS (ES+TOF), m/z
calcd for C20H22N3O2 ([M+H]
+), 336.1712; found: 336.1715; HPLC
(Method A): 95.9%, tR=5.07 min. N-(4-Methoxybenzyl)-2-phenylacry-
lamide (6 i) was obtained as an off-white solid, yield 0.31 g (50%);
m.p. 100–102 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.64; 1H
NMR ([D6]DMSO): δ 8.66 (t, J=5.9 Hz, 1H, NH), 7.43 (d, J=4.7 Hz,
2H, Ar), 7.36 (m, 3H, Ar), 7.25 (d, J=8.7 Hz, 2H, Ar), 6.91 (d, J=
8.7 Hz, 2H, Ar), 5.77 (s, 1H, C=CHaHb), 5.65 (s, 1H, C=CHaHb), 4.33
(d, J=6.1 Hz, 2H, NHCH2), 3.75 (s, 3H, CH3);
13C NMR ([D6]DMSO): δ
168.58 (C, C=O), 158.66 (C, C-OCH3), 145.72 (C, C=CH2), 137.22 (C,
Ar), 132.02 (C, Ar), 129.00 (2×CH, Ar), 128.78 (2×CH, Ar), 128.54
(CH, Ar), 127.50 (2×CH, Ar), 118.04 (C=CH2), 114.18 (2×CH, Ar),
55.53 (CH3), 42.27 (NHCH2); elemental analysis calcd (%) for
C17H17NO2 (267.3268): C 76.38, H 6.41, N 5.24; found: C 76.35, H 6.30,
N 5.13.
N-(3,4-Dimethoxybenzyl)-3-(1H-imidazol-1-yl)-2-phenylpropana-
mide (5 j, R1=3,4-diOCH3, R
2=H) and N-(3,4-dimethoxybenzyl)-2-
phenylacrylamide (6 j, R1=3,4-diOCH3, R
2=H). Prepared from 3-
((3,4-dimethoxybenzyl)amino)-3-oxo-2-phenylpropyl methanesulfo-
nate (4j; 0.52 g, 1.30 mmol) and purified by gradient column
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chromatography eluting the alkene (6 j) with petroleum ether/
EtOAc 60 :40 v/v, followed by the imidazole (5 j) with CH2Cl2/MeOH
90 :10 v/v. N-(3,4-Dimethoxybenzyl)-3-(1H-imidazol-1-yl)-2-phenylpro-
panamide (5 j) was obtained as a pale yellow oil, yield 0.25 g (51%);
TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR ([D6]DMSO): δ
8.55 (t, J=5.8 Hz, 1H, NH), 7.53 (brs, 1H, imid), 7.41 (d, J=7.2 Hz,
2H, Ar), 7.34 (t, J=7.4 Hz, 2H, Ar), 7.28 (t, J=7.3 Hz, 1H, Ar), 7.09
(brs, 1H, imid), 6.85 (brs, 1H, imid), 6.80 (d, J=8.2 Hz, 1H, Ar), 6.60
(d, J=1.8 Hz, 1H, Ar), 6.56 (dd, J=1.8, 8.2 Hz, 1H, Ar), 4.64 (dd, J=
9.6, 13.5 Hz, 1H, CHCHaHb), 4.23 (dd, J=7.5, 13.5 Hz, 1H, CHCHaHb),
4.16 (d, J=5.8 Hz, 2H, NHCHaHb), 4.01 (dd, J=5.7, 9.5 Hz, 1H,
CHCHaHb), 3.70 (s, 3H, CH3), 3.58 (s, 3H, CH3);
13C NMR ([D6]DMSO): δ
170.93 (C, C=O), 149.10 (C, COCH3), 148.17 (C, COCH3), 138.16 (C,
Ar), 131.88 (C, Ar), 128.93 (3×CH, Ar (2) and imid (1)), 128.52 (CH,
imid), 128.27 (3×CH, Ar (2) and imid (1)), 127.81 (CH, Ar), 119.55
(CH, Ar), 112.05 (CH, Ar), 111.14 (CH, Ar), 56.02 (OCH3), 55.67 (OCH3),
53.35 (CHCH2imid), 48.80 (CHCH2imid), 42.21 (NHCH2); LRMS (ES+
TOF, m/z): 366.18 [C21H23N3O3 + H]
+; HRMS (ES+ TOF), m/z calcd for
C21H24N3O3 ([M+H]
+), 366.1818; found: 366.1826; HPLC (Method A):
99.9%, tR=4.81 min. N-(3,4-Dimethoxybenzyl)-2-phenylacrylamide
(6 j) was obtained as white solid, yield 0.09 g (23%); m.p. 102–
104 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.64; 1H NMR ([D6]
DMSO): δ 8.66 (t, J=6.0 Hz, 1H, NH), 7.44 (m, 2H, Ar), 7.36 (m, 3H,
Ar), 6.92 (m, 2H, Ar), 6.84 (dd, J=1.9, 8.2 Hz, 1H, Ar), 5.78 (s, 1H,
C=CHaHb), 5.65 (s, 1H, C=CHaHb), 4.33 (d, J=6.1 Hz, 2H, NHCH2),
3.75 (s, 3H, CH3), 3.74 (s, 3H, CH3);
13C NMR ([D6]DMSO): δ 168.68 (C,
C=O), 149.13 (C, C-OCH3), 148.21 (C, C-OCH3), 145.75 (C, C=CH2),
137.19 (C, Ar), 132.52 (C, Ar), 128.79 (2×CH, Ar), 128.57 (CH, Ar),
127.45 (2×CH, Ar), 119.74 (CH, Ar), 117.87 (C=CH2), 112.24 (CH, Ar),
111.69 (CH, Ar), 56.05 (CH3), 55.86 (CH3), 42.54 (NHCH2); elemental
analysis calcd (%) for C18H19NO3 (299.3530): C 72.71, H 6.44, N 4.71;
found: C 72.59, H 6.46, N 4.82.
N-(4-Chlorobenzyl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propanamide
(5k, R1=4-Cl, R2=H). Prepared from 3-((4-chlorobenzyl)amino)-3-
oxo-2-phenylpropyl methanesulfonate (4c; 0.59 g, 1.61 mmol) and
purified by gradient column chromatography eluting the triazole
(5k) with petroleum ether/EtOAc 10 :90 v/v. Product was obtained
as a white solid, yield 0.22 g (40%); m.p. 113–115 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR ([D6]DMSO): δ
8.72 (t, J=6.0 Hz, 1H, NH), 8.32 (s, 1H, triaz), 7.99 (s, 1H, triaz), 7.20
(m, 5H, Ar), 7.28 (d, J=8.4 Hz, 2H, Ar), 6.97 (d, J=8.5 Hz, 2H, Ar),
4.83 (dd, J=9.2, 13.8 Hz, 1H, CHCHaHb), 4.44 (dd, J=6.5, 13.5 Hz,
1H, CHCHaHb), 4.27 (m, 2H, CHCHaHb+NHCHaHb), 4.08 (dd, J=5.5,
15.6 Hz, NHCHaHb); 13C NMR ([D6]DMSO): δ 170.74 (C, C=O), 151.99
(CH, triaz), 145.08 (CH, triaz), 138.58 (C, Ar), 137.94 (C, C  Cl), 137.47
(C, C  Cl), 131.68 (C, Ar), 129.9.36 (CH, Ar), 129.07 (2×CH, Ar), 129.02
(2×CH, Ar), 128.78 (CH, Ar), 128.54 (2×CH, Ar), 128.23 (CH, Ar),
51.56 (CHCH2triaz), 51.10 (CHCH2triaz), 41.72 (NHCH2); elemental
analysis calcd (%) for C18H17ClN4O (340.8115): C 63.44; H, 5.03; N,
16.43 ; found: C 63.22; H, 5.01; N, 16.33; HPLC (Method A): 99.7%,
tR=4.91 min.
tert-Butyl (4-((2-phenyl-3-(1H-1,2,4-triazol-1-yl)propanamido)
methyl)phenyl)carbamate (5 l, R1=NHBoc, R2=H) and tert-butyl
(4-((2-phenylacrylamido)methyl)phenyl)carbamate (6 l, R1=
NHBoc, R2=H). Prepared from 3-((4-((tert-butoxycarbonyl)amino)
benzyl)amino)-3-oxo-2-phenylpropyl methanesulfonate (4k; 0.62 g,
1.39 mmol) and purified by gradient column chromatography
eluting the alkene (6 l) with petroleum ether/EtOAc 60 :40 v/v,
followed by the imidazole (5 l) with CH2Cl2/MeOH 90 :10 v/v. tert-
Butyl (4-((2-phenyl-3-(1H-1,2,4-triazol-1-yl)propanamido)methyl)
phenyl)carbamate (5 l) was obtained as a pale yellow oil, yield 0.49 g
(84%); TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.0;
1H NMR
(CDCl3): δ 7.80 (s, 1H, triazole), 7.76 (s, 1H, triazole), 7.18 (m, 7H, Ar),
6.81 (d, J=8.5 Hz, 2H, Ar), 6.61 (s, 1H, NH), 6.10 (t, J=5.6 Hz, 1H,
NHCHaHb), 4.83 (dd, J=8.7, 13.6 Hz, 1H, CHCHaHb), 4.23 (ddd, J=
6.1, 14.7, 21.0 Hz, 2H, CHCHaHb and NHCHaHb), 4.11 (dd, J=5.5,
9.2, 14.8 Hz, 1H, NHCHaHb), 3.97 (dd, J=6.2, 8.7 Hz, 1H, CHCHaHb),
1.39 (s, 9H, C(CH3)3);
13C NMR (CDCl3): δ 170.26 (C, C=O), 152.79 (C,
C=O), 151.99 (CH, triaz), 144.21 (CH, triaz), 137.77 (C, Ar), 135.96 (C,
Ar), 132.12 (C, Ar), 129.25 (2×CH, Ar), 128.35 (CH, Ar), 128.14 (3×
CH, Ar), 127.81 (2×CH, Ar), 118.75 (CH, Ar), 80.60 (C(CH3)3), 54.71
(CHCH2), 52.05 (CHCH2), 42.15 (NHCH2), 28.33 (C(CH3)3); HRMS (ESI),
m/z calcd for C23H28N5O3 ([M+H]
+), 422.2218; found: 422.2187;
HPLC (Method A): 99.7%, tR=4.82 min. tert-Butyl (4-((2-phenyl-
acrylamido)methyl)phenyl)carbamate (6 l) was obtained as white
solid, yield 0.06 g (9%); m.p. 136–138 °C; TLC (petroleum ether/
EtOAc 1 :1 v/v); Rf=0.7;
1H NMR (CDCl3): δ 7.38 (m, 5H, Ar), 7.33 (d,
J=8.5 Hz, 2H, Ar), 7.21 (d, J=8.5 Hz, 2H, Ar), 6.53 (s, 1H, NH), 6.21
(d, J=1.3 Hz, 1H, C=CHaHb), 5.97 (brs, 1H, NH), 5.65 (d, J=1.3 Hz,
1H, C=CHaHb), 4.49 (d, J=5.6 Hz, 2H, NHCH2), 1.53 (s, 9H, C(CH3)3);
13C NMR (CDCl3): δ 167.07 (C, C=O), 152.73 (C, C=O), 144.61 (C,
C=CHaHb), 137.77 (C, Ar), 136.97 (C, Ar), 132.60 (C, Ar), 128.77 (2×
CH, Ar), 128.57 (CH, Ar), 128.50 (3×CH, Ar), 128.82 (2×CH, Ar),
122.64 (C=CH2), 118.78 (CH, Ar), 80.64 (C(CH3)3), 43.46 (NHCH2),
28.34 (C(CH3)3); HRMS (ESI), m/z calcd for C21H25N2O3 ([M+H]
+),
353.1876; found: 353.1860.
N-(4-Chlorobenzyl)-2-phenylacrylamide (6c, R1=4-Cl, R2=H). Pre-
pared from 3-((4-chlorobenzyl)amino)-3-oxo-2-phenylpropyl meth-
anesulfonate (4c; 0.38 g, 1.03 mmol) and purified by gradient
column chromatography eluting the alkene (6c) with petroleum
ether/EtOAc 70 :30 v/v. Product was obtained as a white solid, yield
0.09 g (23%); m.p. 118–120 °C; TLC (petroleum ether/EtOAc 1 :1 v/
v); Rf=0.75;
1H NMR ([D6]DMSO): δ 8.76 (t, J=5.9 Hz, 1H, NH), 7.38
(m, 9H, Ar), 5.79 (s, 1H, C=CHaHb), 5.69 (s, 1H, C=CHaHb), 4.37 (d,
J=6.1 Hz, 2H, NHCH2;
13C NMR ([D6]DMSO): δ 168.72 (C, C=O),
145.53 (C, C=CH2), 139.13 (C, Ar), 137.12 (C, Ar), 131.77 (C, C  Cl),
129.54 (2×CH, Ar), 128.80 (2×CH, Ar), 128.73 (2×CH, Ar), 128.59
(CH, Ar), 127.54 (2×CH, Ar), 118.40 (C=CH2), 42.22 (NHCH2);
elemental analysis calcd (%) for C16H14ClNO (271.7457): C 70.72, H
5.19, N 5.15; found: C 70.44, H 5.16, N 5.04.
2-Phenyl-N-(4-(phenylsulfonamido)benzyl)-3-(1H-1,2,4-triazol-1-
yl)propanamide (12a, R1=H) and 2-phenyl-N-(4-(phenylsulfona-
mido)benzyl) acrylamide (13a, R1=H). Prepared from 3-oxo-2-
phenyl-3-((4-(phenylsulfonamido)benzyl)amino)propyl methanesul-
fonate (11a; 0.32 g, 0.65 mmol) and purified by gradient column
chromatography eluting the alkene (13a) with petroleum ether/
EtOAc 40 :60 v/v, followed by the triazole (12a) with CH2Cl2/MeOH
90 :10 v/v. 2-Phenyl-N-(4-(phenylsulfonamido)benzyl)-3-(1H-1,2,4-tria-
zol-1-yl)propanamide (12a) was obtained as a white solid, yield
0.06 g (19%); m.p. 96–98 °C; TLC (petroleum ether/EtOAc 1 :1 v/v);
Rf=0.0;
1H NMR ([D6]DMSO): δ 10.20 (brs, 1H, NHSO2), 8.58 (t, J=
5.9 Hz, 1H, NH), 8.30 (s, 1H, triazole), 7.92 (s, 1H, triazole), 7.73 (d, J=
7.1 Hz, 2H, Ar), 7.61 (t, J=7.4 Hz, 1H, Ar), 7.54 (t, J=7.5 Hz, 2H, Ar),
7.31 (m, 5H, Ar), 6.93 (d, J=8.6 Hz, 2H, Ar), 6.79 (d, J=8.6 Hz, 2H,
Ar), 4.80 (dd, J=9.1, 13.5 Hz, 1H, CHCHaHb), 4.42 (dd, J=6.6,
13.5 Hz, 1H, CHCHaHb), 4.18 (ddd, J=6.5, 15.4, 20.9 Hz, 2H,
CHCHaHb+NHCHaHb), 3.97 (dd, J=5.8, 15.4 Hz, 1H, NHCHaHb); 13C
NMR ([D6]DMSO): δ 170.59 (C, C=O), 151.89 (CH, triazole), 145.63
(CH, triazole), 139.93 (C, Ar), 137.50 (C, Ar), 136.68 (C, Ar), 135.23 (C,
Ar), 133.33 (CH, Ar), 129.70 (2×CH, Ar), 128.96 (2×CH, Ar), 128.21
(2×CH, Ar), 128.05 (2×CH, Ar), 127.91 (CH, Ar), 127.09 (2×CH, Ar),
120.51 (2×CH, Ar), 51.52 (CHCH2), 51.08 (CHCH2), 41.78 (NHCH2);
HRMS (ESI), m/z calcd for C24H24N5O3S ([M+H]
+), 462.1594; found:
462.1613; HPLC (Method A): 99.9%, tR=4.68 min. 2-Phenyl-N-(4-
(phenylsulfonamido)benzyl) acrylamide (13a) was obtained as white
waxy solid, yield 0.15 g (51%); TLC (petroleum ether/EtOAc 1 :1 v/v);
Rf=0.46;
1H NMR ([D6]DMSO): δ 10.25 (brs, 1H, NHSO2), 8.63 (t, J=
6.0 Hz, 1H, NH), 7.77 (d, J=7.1 Hz, 2H, Ar), 7.60 (t, J=7.1 Hz, 1H, Ar),
7.54 (t, J=7.45 Hz, 2H, Ar), 7.36 (m, 5H, Ar), 7.16 (d, J=8.6 Hz, 2H,
Ar), 7.06 (d, J=8.6 Hz, 2H, Ar), 5.76 (s, 1H, C=CHaHb), 5.64 (s, 1H,
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C=CHaHb), 4.27 (d, J=6.1 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ
168.65 (C, C=O), 145.56 (C, C=CH2), 140.00 (C, Ar), 137.13 (C, Ar),
136.71 (C, Ar), 135.84 (C, Ar), 133.33 (CH, Ar), 129.71 (2×CH, Ar),
128.77 (2×CH, Ar), 128.55 (CH, Ar), 128.42 (2×CH, Ar), 127.49 (2×
CH, Ar), 127.11 (2×CH, Ar), 120.69 (2×CH, Ar), 118.18 (C=CH2), 42.21
(NHCH2); HRMS (ESI), m/z calcd for C22H21N2O3S ([M+H]
+), 393.1267;
found: 393.1255.
N-(4-((4-Fluorophenyl)sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-
triazol-1-yl) propanamide (12b, R1=4-F) and N-(4-((4-fluorophen-
yl)sulfonamido)benzyl)-2-phenylacrylamide (13b, R1=4-F). Pre-
pared from 3-oxo-2-phenyl-3-((4-(4-fluorophenylsulfonamido)benzyl)
amino)propyl methanesulfonate (11b; 0.31 g, 0.62 mmol) and puri-
fied by gradient column chromatography eluting the alkene (13b)
with petroleum ether/EtOAc 50 :50 v/v, followed by the triazole
(12b) with CH2Cl2/MeOH 90 :10 v/v. N-(4-((3-Fluorophenyl)
sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl) propanamide
(12b) was obtained as a white solid, yield 0.09 g (30%); m.p. 78–
80 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.0; 1H NMR ([D6]
DMSO): δ 10.21 (brs, 1H, NHSO2), 8.59 (t, J=5.9 Hz, 1H, NH), 8.31 (s,
1H, triazole), 7.93 (s, 1H, triazole), 7.79 (dd, J=5.2, 8.9 Hz, 2H, Ar),
7.34 (m, 7H, Ar), 6.93 (d, J=8.5 Hz, 2H, Ar), 6.81 (d, J=8.5 Hz, 2H,
Ar), 4.81 (dd, J=9.1, 13.5 Hz, 1H, CHCHaHb), 4.43 (dd, J=6.6,
13.5 Hz, 1H, CHCHaHb), 4.19 (m, 2H, CHCHaHb+NHCHaHb), 3.99
(dd, J=5.4, 15.4 Hz, 1H, NHCHaHb); 13C NMR ([D6]DMSO): δ 170.60
(C, C=O), 165.73 (C, Ar), 163.73 (C, Ar), 151.90 (CH, triazole), 143.33
(CH, triazole), 137.51 (C, Ar), 136.49 (C, Ar), 135.48 (C, Ar), 130.21
(CH, Ar), 130.13 (CH, Ar), 128.96 (2×CH, Ar), 128.22 (2×CH, Ar),
128.08 (2×CH, Ar), 127.90 (CH, Ar), 120.76 (2×CH, Ar), 117.00 (CH,
Ar), 116.82 (CH, Ar), 51.53 (CHCH2), 51.09 (CHCH2), 41.78 (NHCH2);
elemental analysis calcd (%) for C24H22FN5O3S·0.1H2O (481.32942): C
59.89, H 4.65, N 14.55; found: C 59.52, H 4.49, N 14.26; HPLC
(Method A): 99.9%, tR=4.69 min. N-(4-((4-Fluorophenyl)sulfonamido)
benzyl)-2-phenylacrylamide (13b) was obtained as a white solid,
yield 0.12 g (41%); m.p. 136–138 °C; TLC (petroleum ether/EtOAc
1 :1 v/v); Rf=0.5;
1H NMR ([D6]DMSO): δ 10.27 (brs, 1H, NHSO2), 8.64
(t, J=6.1 Hz, 1H, NH), 7.81 (dd, J=5.2, 9.0 Hz, 2H, Ar), 7.36 (m, 7H,
Ar), 7.17 (d, J=8.6 Hz, 2H, Ar), 7.06 (d, J=8.6 Hz, 2H, Ar), 5.76 (s, 1H,
C=CHaHb), 5.64 (s, 1H, C=CHaHb), 4.28 (d, J=6.1 Hz, 2H, NHCH2);
13C NMR ([D6]DMSO): δ 168.65 (C, C=O), 165.73 (C, Ar), 163.73 (C,
Ar), 145.56 (C, C=CH2), 137.13 (C, Ar), 136.50 (C, Ar), 136.09 (C, Ar),
130.22 (CH, Ar), 130.15 (CH, Ar), 128.76 (2×CH, Ar), 128.54 (CH, Ar),
128.47 (2×CH, Ar), 127.49 (2×CH, Ar), 120.93 (2×CH, Ar), 118.20
(C=CH2), 117.02 (CH, Ar), 116.84 (CH, Ar), 42.20 (NHCH2); HRMS (ESI),
m/z calcd for C22H20FN2O3S ([M+H]
+), 411.1173; found: 411.1173.
N-(4-((4-Chlorophenyl)sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-
triazol-1-yl) propanamide (12c, R1=4-Cl) and N-(4-((4-chloro-
phenyl)sulfonamido)benzyl)-2-phenylacrylamide (13c, R1=4-Cl).
Prepared from 3-((4-((4-chlorophenyl)sulfonamido)benzyl)amino)-3-
oxo-2-phenylpropyl methanesulfonate (11c; 0.20 g, 0.41 mmol) and
purified by gradient column chromatography eluting the alkene
(13c) with petroleum ether/EtOAc 50 :50 v/v, followed by the
triazole (12c) with CH2Cl2/MeOH 90 :10 v/v. N-(4-((4-Chlorophenyl)
sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-triazol-1-yl) propanamide
(12c) was obtained as an off-white solid, yield 0.02 g (11%); m.p.
122–124 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=0.0; 1H NMR
([D6]DMSO): δ 10.27 (brs, 1H, NHSO2), 8.59 (t, J=5.9 Hz, 1H, NH),
8.31 (s, 1H, triazole), 7.92 (s, 1H, triazole), 7.72 (d, J=8.8 Hz, 2H, Ar),
7.63 (d, J=8.8 Hz, 2H, Ar), 7.30 (m, 5H, Ar), 6.92 (d, J=8.6 Hz, 2H,
Ar), 6.81 (d, J=8.6 Hz, 2H, Ar), 4.81 (dd, J=9.1, 13.5 Hz, 1H,
CHCHaHb), 4.43 (dd, J=6.6, 13.5 Hz, 1H, CHCHaHb), 4.19 (m, 2H,
CHCHaHb+NHCHaHb), 3.99 (dd, J=5.4, 15.4 Hz, 1H, NHCHaHb); 13C
NMR ([D6]DMSO): δ 170.60 (C, C=O), 151.89 (CH, triazole), 143.81
(CH, triazole), 138.76 (C, Ar), 138.21 (C, C  Cl), 137.51 (C, Ar), 136.33
(C, Ar), 135.61 (C, Ar), 129.89 (2×CH, Ar), 129.07 (2×CH, Ar), 128.96
(2×CH, Ar), 128.22 (2×CH, Ar), 128.12 (2×CH, Ar), 127.90 (CH, Ar),
120.85 (2×CH, Ar), 51.52 (CHCH2), 51.09 (CHCH2), 41.78 (NHCH2);
HRMS (ESI), m/z calcd for C24H23ClN5O3S ([M+H]
+), 455.1119; found:
455.1143; HPLC (Method A): 99.9%, tR=4.75 min. N-(4-((3-Chloro-
phenyl)sulfonamido)benzyl)-2-phenylacrylamide (13c) was obtained
as a white solid, yield 0.10 g (50%); m.p. 164–166 °C; TLC
(petroleum ether/EtOAc 1 :1 v/v); Rf=0.73;
1H NMR ([D6]DMSO): δ
10.33 (brs, 1H, NHSO2), 8.64 (t, J=6.1 Hz, 1H, NH), 7.75 (d, J=8.8 Hz,
2H, Ar), 7.63 (d, J=8.8 Hz, 2H, Ar), 7.36 (m, 5H, Ar), 7.18 (d, J=
8.5 Hz, 2H, Ar), 7.05 (d, J=8.5 Hz, 2H, Ar), 5.76 (s, 1H, C=CHaHb),
5.64 (s, 1H, C=CHaHb), 4.28 (d, J=6.1 Hz, 2H, NHCH2);
13C NMR ([D6]
DMSO): δ 168.67 (C, C=O), 145.55 (C, C=CH2), 138.81 (C, Ar), 138.22
(C, C  Cl), 137.12 (C, Ar), 136.20 (C, Ar), 129.90 (2×CH, Ar), 129.08
(2×CH, Ar), 128.77 (2×CH, Ar), 128.55 (CH, Ar), 128.51 (2×CH, Ar),
127.49 (2×CH, Ar), 121.02 (2×CH, Ar), 118.20 (C=CH2), 42.21
(NHCH2); HRMS (ESI), m/z calcd for C22H20ClN2O3S ([M+H]
+),
427.0884; found: 427.0872.
2-Phenyl-N-(4-(4-methoxyphenylsulfonamido)benzyl)-3-(1H-1,2,4-
triazol-1-yl)propanamide (12d, R1=4-OCH3) and 2-phenyl-N-(4-
(4-methoxyphenylsulfonamido)benzyl)acrylamide (13d, R1=4-
OCH3). Prepared from 3-((4-((4-methoxyphenyl)sulfonamido)benzyl)
amino)-3-oxo-2-phenylpropyl methanesulfonate (11d; 0.40 g,
0.77 mmol) and purified by gradient column chromatography
eluting the alkene (13d) with petroleum ether/EtOAc 40 :60 v/v,
followed by the triazole (12d) with CH2Cl2/MeOH 90 :10, v/v. N-(4-
((4-Methoxyphenyl)sulfonamido)benzyl)-2-phenyl-3-(1H-1,2,4-triazol-1-
yl) propanamide (12d) was obtained as a white solid, yield 0.07 g
(17%); m.p. 160–162 °C; TLC (petroleum ether/EtOAc 1 :1 v/v); Rf=
0.0; 1H NMR ([D6]DMSO): δ 10.05 (brs, 1H, NHSO2), 8.58 (t, J=5.9 Hz,
1H, NH), 8.31 (s, 1H, triazole), 7.92 (s, 1H, triazole), 7.67 (d, J=9.0 Hz,
2H, Ar), 7.31 (m, 5H, Ar), 7.05 (d, J=9.0 Hz, 2H, Ar), 6.93 (d, J=
8.5 Hz, 2H, Ar), 6.79 (d, J=8.5 Hz, 2H, Ar), 4.81 (dd, J=9.0, 13.4 Hz,
1H, CHCHaHb), 4.43 (dd, J=6.6, 13.5 Hz, 1H, CHCHaHb), 4.19 (m, 2H,
CHCHaHb+NHCHaHb), 3.98 (dd, J=5.4, 15.4 Hz, 1H, NHCHaHb),
3.80 (s, 3H, OCH3);
13C NMR ([D6]DMSO): δ 170.59 (C, C=O), 162.85
(C, C-OCH3), 151.84 (CH, triazole), 145.04 (CH, triazole), 137.57 (CH,
Ar), 136.97 (C, Ar), 135.00 (C, Ar), 131.74 (C, Ar), 129.31 (2×CH, Ar),
128.93 (2×CH, Ar), 128.22 (2×CH, Ar), 128.02 (2×CH, Ar), 128.87
(CH, Ar), 120.36 (2×CH, Ar), 114.81 (2×CH, Ar), 56.09 (OCH3), 51.58
(CHCH2), 51.18 (CHCH2), 41.87 (NHCH2); HRMS (ESI), m/z calcd for
C25H26N5O4S ([M+H]
+), 492.1706; found: 492.1695; HPLC (Method
A): 99.99%, tR=4.68 min. N-(4-((4-Methoxyphenyl)sulfonamido)
benzyl)-2-phenylacrylamide (13d) was obtained as a white solid,
yield 0.17 g (44%); m.p. 98–100 °C; TLC (petroleum ether/EtOAc 1 :1
v/v); Rf=0.33;
1H NMR ([D6]DMSO): δ 10.11 (brs, 1H, NHSO2), 8.63 (t,
J=6.1 Hz, 1H, NH), 7.69 (d, J=9.0 Hz, 2H, Ar), 7.38 (m, 5H, Ar), 8.65
(d, J=8.7 Hz, 2H, Ar), 7.05 (d, J=8.8 Hz, 4H, Ar), 5.76 (s, 1H,
C=CHaHb), 5.64 (s, 1H, C=CHaHb), 4.27 (d, J=6.1 Hz, 2H, NHCH2),
3.79 (s, 3H, OCH3);
13C NMR ([D6]DMSO): δ 168.65 (C, C=O), 162.84
(C, C-OCH3), 145.56 (C, C=CH2), 136.97 (C, Ar), 135.57 (C, Ar), 131.64
(C, Ar), 129.34 (2×CH, Ar), 128.76 (2×CH, Ar), 128.54 (CH, Ar),
128.38 (2×CH, Ar), 127.49 (2×CH, Ar), 120.43 (2×CH, Ar), 118.16
(C=CH2), 114.82 (2×CH, Ar), 56.07 (OCH3), 42.21 (NHCH2); HRMS
(ESI), m/z calcd for C23H23N2O4S ([M+H]
+), 423.1379; found:
423.1368.
Computational methods
Molecular modelling and docking. Docking studies were per-
formed using the MOE program[35] and CaCYP51 (PDB ID:
5FSA[22]) to generate pdb files of the CaCYP51 crystal structure
and representative short (5f) and extended (12c) azole
derivative complexes. All minimisations were performed with
MOE until a RMSD gradient of 0.01 Kcal/mol/A with the
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MMFF94 forcefield and partial charges were automatically
calculated. The charge of the haem iron at physiological pH was
set to 3+ (geometry d2sp3) through the atom manager in MOE.
The Alpha Triangle placement was chosen to determine the
poses, refinement of the results was done using the MMFF94
forcefield, and rescoring of the refined results using the London
ΔG scoring function was applied. The output database dock file
was created with different poses for each ligand and arranged
according to the final score function (S), which is the score of
the last stage that was not set to zero.
Molecular dynamics simulation. Molecular dynamics simula-
tions were run on the wild-type/mutant [Y132H+K143R]
CaCYP51 proteins in complex with fluconazole and the R and S
enantiomers of 5f and 12c. PDB files were first optimised with
protein preparation wizard in Maestro,[36] version 11.8.012 by
assigning bond orders, adding hydrogen, and correcting
incorrect bond types. A default quick relaxation protocol was
used to minimise the MD systems with the Desmond
programme.[36] In Desmond, the volume of space in which the
simulation takes place, the global cell, is built up by regular 3D
simulation boxes, which was utilised as part of this system for
protein interactions. The orthorhombic water box allowed for a
10 Å buffer region between protein atoms and box sides.
Overlapping water molecules were deleted, and the systems
were neutralised with Na+ ions and salt concentration 0.15 M.
Force-field parameters for the complexes were assigned using
the OPLS_2005 forcefield, that is, a 100 ns molecular dynamic
run in the NPT ensemble (T=300 K) at a constant pressure of
1 bar. Energy and trajectory atomic coordinate data were
recorded at each 1.2 ns.
Binding affinity (ΔG) calculations. Prime/MMGBAS,[37] avail-
able in Schrödinger Prime suite,[36] was used to calculate the
binding free energy of the ligands with CaCYP51.
ΔG (bind)=E_complex (minimised)  (E_ligand (minimised)
+E_receptor (minimised))
The mean ΔG (bind) was calculated from each frame from
the point where the complex reached equilibrium to the final
frame of the MD stimulation.
Biological assays
Recombinant CYP51 protein studies. Candida albicans CYP51
(CaCYP51) and truncated human CYP51 (Δ60HsCYP51) proteins
were expressed in Escherichia coli, isolated and purified as
previously described.[18,21] The Δ60HsCYP51 protein was shown
to have near identical azole binding properties to the full-
length HsCYP51.[21] CYP51 concentrations were determined by
dithionite-reduced carbon monoxide difference spectroscopy[39]
using an extinction coefficient for the red-shifted soret peak at
~450 nm of 91 mM  1 cm  1.[32] Absolute spectra for both CYP51
enzymes between 300 and 700 nm were also determined.[40]
Azole antifungal compounds were progressively titrated against
3 μM native (azole titratable) CYP51 as previously described[21]
and the type II absorbance difference spectra between 500 and
350 nm measured after each incremental addition of azole. All
azole ligand binding determinations were performed in tripli-
cate, except the binding of compound 12c with Δ60HsCYP51
which was performed six times. CYP51 protein samples were
diluted with 0.1 M Tris·HCl (pH 8.1) and 25% (w/v) glycerol to
the required concentration.
Susceptibility testing of C. albicans strains. Minimum Inhib-
itory Concentration (MIC) determinations were performed
according to recommendations outlined in the Clinical and
Laboratory Standards Institute (CLSI) document M27-S4;[28] this
includes testing in RPMI-1640 with 0.165 M MOPS as the buffer
(pH 7.0), an inoculum size of 1–5×104 cells mL  1, and
incubation at 37 °C for 48 h. The MICs were measured as the
lowest concentrations of each antifungal agent that resulted in
an 80% reduction in turbidity as compared with a drug-free,
growth control well. Stock solutions of each agent were
prepared in DMSO. Further dilutions were made in RPMI-1640,
and the final concentration of DMSO was 1% (v/v). The final
testing concentrations for all compounds ranged from 0.03–
16 μgmL  1.
CYP51 reconstitution assays. IC50 values were determined for
individual azole compounds[18,30] using lanosterol as substrate.
Azoles were introduced using 2.5 μL of stock solutions in
DMSO. CaCYP51 assays contained 1 μM CaCYP51 and 2 μM
Homo sapiens cytochrome P450 reductase (HsCPR – UniProtKB
accession number P16435) and were incubated for 20 min at
37 °C. HsCYP51 assays contained 0.25 μM Δ60HsCYP51 and
1 μM HsCPR and were incubated for 10 min at 37 °C. Each IC50
experiment was performed in duplicate. IC50 is defined here as
the inhibitory concentration of compound that causes a 50%
reduction in observed enzyme activity under the stated assay
conditions.
Dissociation constant (Kd). The Kd for each CYP51-azole
complex was determined by non-linear regression (Levenberg-
Marquardt algorithm) using a rearrangement of the Morrison
equation for tight ligand binding.[34] Where ligand binding was
weaker, the Michaelis-Menten equation was used to fit the data
(Figure S5). Kd values were determined for each of the three
replicate titrations per azole compound and then mean Kd
values and standard deviations calculated.
Sterol profile analysis of C. albicans strains. Sterol extractions
were performed on cells grown in 10 mL of MOPS buffered
(0.165 M) RPMI-1640, pH 7.0 containing either DMSO alone (1%
v/v), or DMSO containing antifungal (final concentration
0.06 μgmL  1 fluconazole, 0.06 μgmL  1 5d, 0.015 μgmL  1 5f or
0.5 μgmL  1 12c). The culture medium was then innoculted with
C. albicans, (either CA14 or SC5314), to a final density of 5×
104 cellsmL  1 and the cultures grown at 37 °C, 180 rpm, for
18 h. Cells were pelleted and washed with ddH2O and non-
saponifiable lipids were extracted using methanolic KOH as
reported previously.[41] Samples were dried in a vacuum
centrifuge and were derivatised by the addition of 100 μL 90%
BSTFA / 10% TMCS (Sigma), 200 μL anhydrous pyridine (Sigma)
and heating for 2 h at 80 °C. TMS-derivatised sterols were
analysed and identified by using GC/MS (Thermo 1300 GC
coupled to a Thermo ISQ mass spectrometer, Thermo Scientific)
with reference to retention times and fragmentation spectra for
known standards. GC/MS data files were analysed using
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Xcalibur software (Thermo Scientific) to determine sterol
profiles for all isolates and to integrate peak areas.
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